Adeno-associated virus compositions and methods of use thereof

Replication-defective AAV vectors are used to correct F8 gene mutations in hemophilia A, offering a promising treatment by enabling sustainable Factor VIII production, thus addressing the limitations of current therapies.

WO2024229281A1PCT designated stage expired Publication Date: 2024-11-07CITY OF HOPE
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/027526
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-02
Filing Date
2024-05-02
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

Current treatments for hemophilia A, caused by Factor VIII deficiency, rely on lifelong blood transfusions or weekly infusions of recombinant Factor VIII, leading to significant economic and quality of life burdens with no known cure.

Method used

The use of replication-defective adeno-associated virus (AAV) vectors that transduce cells with a correction genome, including editing elements, homology arms, and an F8 coding sequence to correct mutations in the F8 gene, specifically targeting exons 1-13, 14, or 15-26, without co-administering exogenous nucleases.

Benefits of technology

This approach potentially provides a durable correction of Factor VIII gene mutations, reducing the need for frequent infusions and improving the quality of life for individuals with hemophilia A by promoting sustainable production of functional Factor VIII protein.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024027526_07112024_PF_FP_ABST
    Figure US2024027526_07112024_PF_FP_ABST
Patent Text Reader

Abstract

Provided herein, inter alia, are compositions and methods related to correcting mutations in the F8 gene using AAVHSC-mediated nuclease-free genome- editing.
Need to check novelty before this filing date? Find Prior Art

Description

AD ENO- ASSOCIATED VIRUS COMPOSITIONS AND METHODS OF USE THEREOFREFERENCE TO SEQUENCE LISTING

[0001] This application incorporates by reference a Computer Readable Form of a Sequence Listing in ASCII text format submitted with this application, entitled 048440- 870001WO_Sequence Listing.xml, was created on April 30, 2024, and is 99,068 bytes in size.BACKGROUND

[0002] Factor VIII (FVIII), also known as anti -hemophilic factor, is a circulating glycoprotein that is important for normal blood clotting. Factor VIII is produced by liver sinusoidal endothelial cells and endothelial cells outside of the liver. This protein circulates in the bloodstream in an inactive form, bound to another molecule called von Willebrand factor (vWF), until an injury' that damages blood vessels occurs. In response to injury, FVIII is activated and separates from vWF. The active protein, FVIIIa, interacts with another coagulation factor called factor IX to initiate a cascade of additional chemical reactions that form a blood clot.

[0003] Hemophilia A, also called factor VIII deficiency or classic hemophilia, is an inherited or spontaneous genetic disorder caused by missing or defective factor VIII. It is inherited as an X-linked recessive trait, with no known cure. Clinically, hemophilia A is characterized by internal or external bleeding episodes. Due to their inability to form clots, primary management consists of either lifelong blood transfusions or weekly infusions of recombinant FVIII, resulting in a staggering economic and quality of life cost.

[0004] F8, the gene for FVIII is located on the long arm of chromosome X, within the Xq28 region. The gene represents 186 kb of the X chromosome. It comprises a 26 exons and 25 introns. Mature FVIII is a single-chain polypeptide containing 2332 amino acids. Approximately 40% of cases of severe FVIII deficiency arise from a large inversion involving intron 22 that disrupts the F8 gene. Deletions, insertions, and point mutations account for the remaining 50-60% of the F8 defects that cause hemophilia A.

[0005] Provided herein are solutions to these and other problems in the art.BRIEF SUMMARY

[0006] Described herein, inter alia, are compositions and methods for correcting heterogeneous F8 gene mutations associated with hemophilia A.

[0007] In an aspect, provide herein is a method for correcting a mutation in an F8 gene in a cell, the method comprising transducing the cell with a replication-defective adeno-associated virus (AAV) comprising (a) an AAV capsid; and (b) an N-terminal (N-ter) correction genome comprising: (i) an editing element for editing a target locus in the F8 gene; (li) a 5' homology arm nucleotide sequence 5' to the editing element having homology to a first genomic region 5' to the target locus; (iii) a 3' homology arm nucleotide sequence 3' to the editing element having homology to a second genomic region 3' to the target locus; and (iv) an F8 coding sequence; wherein the F8 coding sequence comprises at least two consecutive exons selected from the group consisting of exons 1 to 13 and exon 14, or a portion thereof; and, wherein the cell is transduced without co-transducing or co-administering an exogenous nuclease or a nucleotide sequence that encodes an exogenous nuclease.

[0008] In an aspect, provide herein is a method for correcting a mutation in an F8 gene in a cell, the method comprising transducing the cell with a replication-defective adeno-associated virus (AAV) comprising (a) an AAV capsid; and (b) a central (CEN) correction genome comprising: (i) an editing element for editing a target locus in the F8 gene; (li) a 5' homology arm nucleotide sequence 5' to the editing element having homology to a first genomic region 5' to the target locus; (iii) a 3' homology arm nucleotide sequence 3' to the editing element having homology to a second genomic region 3' to the target locus; and (iv) an F8 coding sequence; wherein the F8 coding sequence comprises exon 14; and, wherein the cell is transduced without co-transducing or co-administering an exogenous nuclease or a nucleotide sequence that encodes an exogenous nuclease

[0009] In an aspect, provide herein is a method for correcting a mutation in an F8 gene in a cell, the method comprising transducing the cell with a replication-defective adeno-associated vims (AAV) comprising (a) an AAV capsid; and (b) a C-terminal (C-ter) correction genome comprising: (i) an editing element for editing a target locus in the F8 gene; (ii) a 5' homology arm nucleotide sequence 5' to the editing element having homology to a first genomic region 5' to the target locus; (iii) a 3' homology arm nucleotide sequence 3' to the editing element having homology to a second genomic region 3' to the target locus; and (iv) an F8 coding sequence; wherein the F8 coding sequence comprises at least two consecutive exons selectedfrom the group consisting of exon 15 to 26 and exon 14 or a portion thereof; and, wherein the cell is transduced without co-transducing or co-administering an exogenous nuclease or a nucleotide sequence that encodes an exogenous nuclease.

[0010] In an aspect, provide herein is a method for treating a subject having a disease or disorder associated with a mutation in an F8 gene, the method comprising administering to the subject an effective amount of a replication-defective recombinant adeno-associated virus (AAV) comprising: (a) an AAV capsid; and (b) a correction genome comprising: (i) an editing element for editing a target locus in the F8 gene; (ii) a 5' homology arm nucleotide sequence 5' to the editing element having homology to a first genomic region 5' to the target locus; (iii) a 3' homology arm nucleotide sequence 3' to the editing element having homology to a second genomic region 3' to the target locus; and (iv) an F8 coding sequence; wherein:(A) the F8 coding sequence comprises at least two consecutive exons selected from the group consisting of exons 1 to 13 and exon 14 or a portion thereof; or(B) the F8 coding sequence comprises exon 14; or(C) the F8 coding sequence comprises at least two consecutive exons selected from the group consisting of exons 15 to 26 and exon 14, or a portion thereof; and, wherein an exogenous nuclease or a nucleotide sequence that encodes an exogenous nuclease is not co-administered to the subject.

[0011] In an aspect, provided herein is replication-defective adeno-associated virus (AAV) comprising: (a) an AAV capsid; and (b) a correction genome comprising: (i) an editing element for editing a target locus in the F8 gene; (ii) a 5' homology arm nucleotide sequence 5' to the editing element having homology to a first genomic region 5' to the target locus; (iii) a 3' homology arm nucleotide sequence 3' to the editing element having homology to a second genomic region 3' to the target locus; and (iv) an F8 coding sequence; wherein the F8 coding sequence consists of the peptide sequences set forth in SEQ. ID NO: 27, SEQ. ID NO: 28, SEQ. ID NO: 29, or portion thereof.

[0012] In an aspect, provided herein is a nucleic acid comprising: (i) an editing element for editing a target locus in an F8 gene; (ii) a 5' homology arm nucleotide sequence 5' to the editing element having homology to a first genomic region 5' to the target locus; (iii) a 3' homology arm nucleotide sequence 3' to the editing element having homology to a second genomic region 3' to the target locus; and, (iv) an F8 coding sequence; wherein the F8 codingsequence consists of the peptide sequences set forth in SEQ. ID NO: 27, SEQ. ID NO: 28, SEQ. ID NO: 29, or portion thereof

[0013] The following embodiments apply to each of the foregoing aspects.

[0014] In embodiments, the F8 coding sequence comprises at least two consecutive exons selected from the group consisting of exons 1 to 13 and exon 14 or a portion thereof. In embodiments, the F8 coding sequence comprises at least three consecutive exons selected from the group consisting of exons 2 to 13 and exon 14 or a portion thereof. In embodiments, the F8 coding sequence comprises at least four consecutive exons selected from the group consisting of exons 2 to 13. In embodiments, the F8 coding sequence compnses at least two consecutive exons selected from the group consisting of exons 2 to 13. In embodiments, the F8 coding sequence comprises at least five consecutive exons selected from the group consisting of exons 2 to 13. In embodiments, the F8 coding sequence compnses at least six consecutive exons selected from the group consisting of exons 2 to 13. In embodiments, the F8 coding sequence comprises at least seven consecutive exons selected from the group consisting of exons 2 to 13. In embodiments, the F8 coding sequence comprises at least eight consecutive exons selected from the group consisting of exons 2 to 13. In embodiments, the F8 coding sequence comprises at least nine consecutive exons selected from the group consisting of exons 2 to 13. In embodiments, the F8 coding sequence compnses at least ten consecutive exons selected from the group consisting of exons 2 to 13. In embodiments, the F8 coding sequence comprises at least eleven consecutive exons selected from the group consisting of exons 2 to 13. In embodiments, the F8 coding sequence compnses twelve consecutive exons selected from the group consisting of exons 2 to 13. In embodiments, the exons correspond to the wild-type sequence of F8 gene as set forth in SEQ ID NOs: 37 to 61. In embodiments, the exons have at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity across the whole sequence the exon.

[0015] In embodiments, the / N coding sequence comprises at least two consecutive exons selected from the group consisting of SEQ. ID NOs: 2 to 13 and optionally a portion of SEQ. ID NO: 14. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 2 and SEQ. ID NO: 3. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 3 and SEQ. ID NO: 4. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth inSEQ. ID NO: 4 and SEQ. ID NO: 5. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 5 and SEQ. ID NO: 6. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 6 and SEQ. ID NO: 7. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 7 and SEQ. ID NO: 8. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 8 and SEQ. ID NO: 9. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 9 and SEQ. ID NO: 10. In embodiments, the FS coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 10 and SEQ. ID NO: 11. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 11 and SEQ. ID NO: 12. In embodiments, the ’ coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 12 and SEQ. ID NO: 13.

[0016] In embodiments, the FS’ coding sequence comprises at least three consecutive exons selected from the group consisting of SEQ. ID NOs: 2 to 13 and optionally a portion of SEQ. ID NO: 14. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 2, SEQ. ID NO: 3, and SEQ. ID NO: 4. In embodiments, the FS' coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 3, SEQ. ID NO: 4, and SEQ. ID NO: 5. In embodiments, the FS coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 4, SEQ. ID NO: 5, and SEQ. ID NO: 6. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 5, SEQ. ID NO: 6, and SEQ. ID NO: 7. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 6, SEQ. ID NO: 7, and SEQ. ID NO: 8. In embodiments, theFS coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 7, SEQ. ID NO: 8, and SEQ. ID NO: 9. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 8, SEQ. ID NO: 9, and SEQ. ID NO: 10. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 9, SEQ. ID NO: 10, and SEQ. ID NO: 11. In embodiments, the N coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 10, SEQ. ID NO: 11, and SEQ. ID NO: 12. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 11, SEQ. ID NO: 12 and SEQ. ID NO: 13.

[0017] In embodiments, the F8 coding sequence comprises at least four consecutive exons selected from the group consisting of SEQ. ID NOs: 2 to 13 and optionally a portion of SEQ.ID NO: 14. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 2, SEQ. ID NO: 3, SEQ. ID NO: 4, and SEQ. ID NO: 5. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 3, SEQ. ID NO: 4, SEQ. ID NO: 5, and SEQ. ID NO: 6. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 4, SEQ. ID NO: 5, SEQ. ID NO: 6, and SEQ. ID NO: 7. In embodiments, the J7# coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 5, SEQ. ID NO: 6, SEQ. ID NO: 7, and SEQ. ID NO: 8. In embodiments, the FS coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 6, SEQ. ID NO: 7, SEQ. ID NO: 8, and SEQ. ID NO: 9. In embodiments, the Fi coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 7, SEQ. ID NO: 8, SEQ. ID NO: 9, and SEQ. ID NO: 10. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 8, SEQ. ID NO: 9, SEQ. ID NO: 10, and SEQ. ID NO: 11. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 9, SEQ. ID NO: 10, SEQ. ID NO: 11, and SEQ. ID NO: 12. In embodiments, theFS coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 10, SEQ. ID NO: 11, SEQ. ID NO: 12, and SEQ. ID NO: 13.

[0018] In embodiments, the F8 coding sequence comprises at least five consecutive exons selected from the group consisting of SEQ. ID NOs: 2 to 13 and optionally a portion of SEQ. ID NO: 14. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 2, SEQ. ID NO: 3, SEQ. ID NO: 4, SEQ. ID NO: 5, and SEQ. ID NO: 6. In embodiments, theFS coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 3, SEQ. ID NO: 4, SEQ. ID NO: 5, SEQ. ID NO: 6, and SEQ. ID NO: 7. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 4, SEQ. ID NO: 5, SEQ. ID NO: 6, SEQ. ID NO: 7, and SEQ. ID NO: 8. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 5, SEQ. ID NO: 6, SEQ. ID NO: 7, SEQ. ID NO: 8, and SEQ. ID NO: 9. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 6, SEQ. ID NO: 7, SEQ. ID NO: 8, SEQ. ID NO: 9, and SEQ. ID NO: 10. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 7, SEQ. ID NO: 8, SEQ. ID NO: 9, SEQ. ID NO: 10, and SEQ. ID NO: 11. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 8, SEQ. ID NO: 9, SEQ. ID NO: 10, SEQ. ID NO: 11, and SEQ. ID NO: 12. Inembodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 9, SEQ. ID NO: 10, SEQ. ID NO: 11, and SEQ. ID NO: 13.

[0019] In embodiments, the F8 coding sequence comprises at least six consecutive exons selected from the group consisting of SEQ. ID NOs: 2 to 13 and optionally a portion of SEQ. ID NO: 14. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 2, SEQ. ID NO: 3, SEQ. ID NO: 4, SEQ. ID NO: 5, SEQ. ID NO: 6, and SEQ. ID NO: 7. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 3, SEQ. ID NO: 4, SEQ. ID NO: 5, SEQ. ID NO: 6, SEQ. ID NO: 7, and SEQ. ID NO: 8. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 4, SEQ. ID NO: 5, SEQ. ID NO: 6, SEQ. ID NO: 7, SEQ. ID NO: 8, and SEQ. ID NO: 9. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 5, SEQ. ID NO: 6, SEQ. ID NO: 7, SEQ. ID NO: 8, SEQ. ID NO: 9, and SEQ. ID NO: 10. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 6, SEQ. ID NO: 7, SEQ. ID NO: 8, SEQ. ID NO: 9, SEQ. ID NO: 10, and SEQ. ID NO: 11. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 7, SEQ. ID NO: 8, SEQ. ID NO: 9, SEQ. ID NO: 10, SEQ. ID NO: 11, and SEQ. ID NO: 12. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 8, SEQ. ID NO: 9, SEQ. ID NO: 10, SEQ. ID NO: 11, SEQ. ID NO: 12, and SEQ. ID NO: 13.

[0020] In embodiments, the F8 coding sequence comprises at least seven consecutive exons selected from the group consisting of SEQ. ID NOs: 2 to 13 and optionally a portion of SEQ. ID NO: 14. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 2, SEQ. ID NO: 3, SEQ. ID NO: 4, SEQ. ID NO: 5, SEQ. ID NO: 6, SEQ. ID NO: 7, and SEQ. ID NO: 8. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 3, SEQ. ID NO: 4, SEQ. ID NO: 5, SEQ. ID NO: 6, SEQ. ID NO: 7, SEQ. ID NO: 8, and SEQ. ID NO: 9. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 4, SEQ. ID NO: 5, SEQ. ID NO: 6, SEQ. ID NO: 7, SEQ. ID NO: 8, SEQ. ID NO: 9, and SEQ. ID NO: 10. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 5, SEQ. ID NO: 6, SEQ. ID NO: 7, SEQ. ID NO: 8, SEQ. ID NO: 9, SEQ. ID NO: 10, and SEQ. ID NO: 11. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 6, SEQ. IDNO: 7, SEQ. ID NO: 8, SEQ. ID NO: 9, SEQ. ID NO: 10, SEQ. ID NO: 11, and SEQ. ID NO: 12. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 7, SEQ. ID NO: 8, SEQ. ID NO: 9, SEQ. ID NO: 10, SEQ. ID NO: 11, SEQ. ID NO: 12, and SEQ. ID NO: 13.

[0021] In embodiments, the F8 coding sequence comprises at least eight consecutive exons selected from the group consisting of SEQ. ID NOs: 2 to 13 and optionally a portion of SEQ. ID NO: 14. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 2, SEQ. ID NO: 3, SEQ. ID NO: 4, SEQ. ID NO: 5, SEQ. ID NO: 6, SEQ. ID NO: 7, SEQ. ID NO: 8, and SEQ. ID NO: 9. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 3, SEQ. ID NO: 4, SEQ. ID NO: 5, SEQ. ID NO: 6, SEQ. ID NO: 7, SEQ. ID NO: 8, SEQ. ID NO: 9, and SEQ. ID NO: 10. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 4, SEQ. ID NO: 5, SEQ. ID NO: 6, SEQ. ID NO: 7, SEQ. ID NO: 8, SEQ. ID NO: 9, SEQ. ID NO: 10, and SEQ. ID NO: 11. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 5, SEQ. ID NO: 6, SEQ. ID NO: 7, SEQ. ID NO: 8, SEQ. ID NO: 9, SEQ. ID NO: 10, SEQ. ID NO: 11, and SEQ. ID NO: 12. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 6, SEQ. ID NO: 7, SEQ. ID NO: 8, SEQ. ID NO: 9, SEQ. ID NO: 10, SEQ. ID NO: 11, SEQ. ID NO: 12, and SEQ ID NO: 13.

[0022] In embodiments, the F8 coding sequence comprises at least nine consecutive exons selected from the group consisting of SEQ. ID NOs: 2 to 13 and optionally a portion of SEQ. ID NO: 14. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 2, SEQ. ID NO: 3, SEQ. ID NO: 4, SEQ. ID NO: 5, SEQ. ID NO: 6, SEQ. ID NO: 7, SEQ. ID NO: 8, SEQ. ID NO: 9, and SEQ. ID NO: 10. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 3, SEQ. ID NO: 4, SEQ. ID NO: 5, SEQ. ID NO: 6, SEQ. ID NO: 7, SEQ. ID NO: 8, SEQ. ID NO: 9, SEQ. ID NO: 10, and SEQ. ID NO: 11. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 4, SEQ. ID NO: 5, SEQ. ID NO: 6, SEQ. ID NO: 7, SEQ. ID NO: 8, SEQ. ID NO: 9, SEQ. ID NO: 10, SEQ. ID NO: 11, and SEQ. ID NO: 12. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 5, SEQ. ID NO: 6, SEQ. ID NO: 7, SEQ. ID NO: 8, SEQ. ID NO: 9, SEQ. ID NO: 10, SEQ. ID NO: 11, SEQ. ID NO: 12, and SEQ. ID NO: 13.

[0023] In embodiments, the F8 coding sequence comprises at least ten consecutive exons selected from the group consisting of SEQ. ID NOs: 2 to 13 and optionally a portion of SEQ. ID NO: 14. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 2, SEQ. ID NO: 3, SEQ. ID NO: 4, SEQ. ID NO: 5, SEQ. ID NO: 6, SEQ. ID NO: 7, SEQ. ID NO: 8, SEQ. ID NO: 9, SEQ. ID NO: 10, and SEQ. ID NO: 11. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 3, SEQ. ID NO: 4, SEQ. ID NO: 5, SEQ. ID NO: 6, SEQ. ID NO: 7, SEQ. ID NO: 8, SEQ. ID NO: 9, SEQ. ID NO: 10, SEQ. ID NO: 11, and SEQ. ID NO: 12. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 4, SEQ. ID NO: 5, SEQ. ID NO: 6, SEQ. ID NO: 7, SEQ. ID NO: 8, SEQ. ID NO: 9, SEQ. ID NO: 10, SEQ. ID NO: 11, SEQ. ID NO: 12, and SEQ. ID NO: 13

[0024] In embodiments, the NS’ coding sequence comprises at least eleven consecutive exons selected from the group consisting of SEQ. ID NOs: 2 to 13 and optionally a portion of SEQ. ID NO: 14. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 2, SEQ. ID NO: 3, SEQ. ID NO: 4, SEQ. ID NO: 5, SEQ. ID NO: 6, SEQ. ID NO: 7, SEQ. ID NO: 8, SEQ. ID NO: 9, SEQ. ID NO: 10, SEQ. ID NO: 11, and SEQ. ID NO: 12. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 3, SEQ. ID NO: 4, SEQ. ID NO: 5, SEQ. ID NO: 6, SEQ. ID NO: 7, SEQ. ID NO: 8, SEQ. ID NO: 9, SEQ. ID NO: 10, SEQ. ID NO: 11, SEQ ID NO: 12, and SEQ. ID NO: 13.

[0025] In embodiments, the F8 coding sequence comprises exons selected from the group consisting of SEQ. ID NOs: 2 to 13 and a portion of SEQ. ID NO: 14. In embodiments, the F8 coding sequence comprises exons selected from the group consisting of SEQ. ID NOs: 2 to 13.

[0026] In embodiments, the NS’ coding sequence comprises exons 2 to 13 and a portion of exon 14. In embodiments, the N coding sequence comprises a proportion of exon 14 such as 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the sequence of exon 14 from the 5' end of exon 14 of the F8 gene. In embodiments, the F8 coding sequence comprises a proportion of exon 14 such as 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the sequence of SEQ. ID NO: 49 from the 5' end of SEQ. ID: NO: 49. In furtherembodiments, the F8 coding sequence comprises a proportion of exon 14 such as 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the sequence of SEQ. ID NO: 14 from the 5' end of SEQ. ID: NO: 14.

[0027] In embodiments, the F8 coding sequence consists of at least 200 contiguous nucleotide sequences within exon 14 of the F8 gene. In embodiments, exon 14 is the nucleotide sequence as set forth in SEQ. ID NO: 49. In embodiments, the F8 coding sequence consists of at least 300 contiguous nucleotide sequences within exon 14. In embodiments, the F8 coding sequence consists of at least 400 contiguous nucleotide sequences within exon 14. In embodiments, the F8 coding sequence consists of at least 500 contiguous nucleotide sequences within exon 14. In embodiments, the F8 coding sequence consists of at least 600 contiguous nucleotide sequences within exon 14. In embodiments, the F8 coding sequence consists of at least 700 contiguous nucleotide sequences within exon 14. In embodiments, the F8 coding sequence consists of at least 800 contiguous nucleotide sequences within exon 14. In embodiments, the F8 coding sequence consists of at least 900 contiguous nucleotide sequences within exon 14. In embodiments, the F8 coding sequence consists of at least 1000 contiguous nucleotide sequences within exon 14. In embodiments, the F8 coding sequence consists of at least 1100 contiguous nucleotide sequences within exon 14. In embodiments, the F8 coding sequence consists of at least 1200 contiguous nucleotide sequences within exon 14. In embodiments, the F8 coding sequence consists of at least 1300 contiguous nucleotide sequences within exon 14. In embodiments, the F8 coding sequence consists of at least 1400 contiguous nucleotide sequences within exon 14. In embodiments, the F8 coding sequence consists of at least 1500 contiguous nucleotide sequences within exon 14. In embodiments, the F8 coding sequence consists of at least 1600 contiguous nucleotide sequences within exon 14. In embodiments, the F8 coding sequence consists of at least 1700 contiguous nucleotide sequences within exon 14. In embodiments, the F8 coding sequence consists of at least 1800 contiguous nucleotide sequences within exon 14. In embodiments, the F8 coding sequence consists of at least 1900 contiguous nucleotide sequences within exon 14.

[0028] In embodiments, the F8 coding sequence consists of at least 200 contiguous nucleotide sequences within SEQ. ID NO: 14. In embodiments, the F8 coding sequence consists of at least 300 contiguous nucleotide sequences within SEQ. ID NO: 14. In embodiments, the F8 coding sequence consists of at least 400 contiguous nucleotide sequences within SEQ. ID NO: 14. In embodiments, the F8 coding sequence consists of atleast 500 contiguous nucleotide sequences within SEQ. ID NO: 14. In embodiments, the F8 coding sequence consists of at least 600 contiguous nucleotide sequences within SEQ. ID NO: 14. In embodiments, the F8 coding sequence consists of at least 700 contiguous nucleotide sequences within SEQ. ID NO: 14. In embodiments, the F8 coding sequence consists of at least 800 contiguous nucleotide sequences within SEQ. ID NO: 14. In embodiments, the F8 coding sequence consists of at least 900 contiguous nucleotide sequences within SEQ. ID NO: 14. In embodiments, the F8 coding sequence consists of at least 1000 contiguous nucleotide sequences within SEQ. ID NO: 14. In embodiments, the F8 coding sequence consists of at least 1100 contiguous nucleotide sequences within SEQ. ID NO: 14. In embodiments, the F8 coding sequence consists of at least 1200 contiguous nucleotide sequences within SEQ. ID NO: 14. In embodiments, the F8 coding sequence consists of at least 1300 contiguous nucleotide sequences within SEQ. ID NO: 14. In embodiments, the F8 coding sequence consists of at least 1400 contiguous nucleotide sequences within SEQ. ID NO: 14. In embodiments, the F8 coding sequence consists of at least 1500 contiguous nucleotide sequences within SEQ. ID NO: 14. In embodiments, the F8 coding sequence consists of at least 1600 contiguous nucleotide sequences within SEQ. ID NO: 14. In embodiments, the F8 coding sequence consists of at least 1700 contiguous nucleotide sequences within SEQ. ID NO: 14. In embodiments, the F8 coding sequence consists of at least 1800 contiguous nucleotide sequences within SEQ. ID NO: 14. In embodiments, the F8 coding sequence consists of at least 1900 contiguous nucleotide sequences within SEQ. ID NO: 14.

[0029] In embodiments, the N' coding sequence comprises a nucleotide sequence as set forth in SEQ. ID NO: 14.

[0030] In embodiments, the 7*7? coding sequence comprises at least two consecutive exons selected from the group consisting of SEQ. ID NOs: 15 to 26 and optionally a portion of SEQ. ID NO: 14. In embodiments, the F8 coding sequence comprise the nucleotide sequences as set forth in SEQ. ID NO: 15 and SEQ. ID NO: 16. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 16 and SEQ. ID NO: 17. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 17 and SEQ. ID NO: 18. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 18 and SEQ. ID NO: 19. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 19 and SEQ. ID NO: 20. In embodiments, the F8coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 20 and SEQ. ID NO: 21. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 21 and SEQ. ID NO: 22. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 22 and SEQ. ID NO: 23. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 23 and SEQ. ID NO: 24. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 24 and SEQ. ID NO: 25. In other embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 25 and SEQ. ID NO: 26.

[0031] In embodiments, the N' coding sequence comprises at least three consecutive exons selected from the group consisting of SEQ. ID NOs: 15 to 26 and optionally a portion of SEQ. ID NO: 14. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 15, SEQ. ID NO: 16, and SEQ. ID NO: 17. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 16, SEQ. ID NO: 17, and SEQ. ID NO: 18. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 17, SEQ. ID NO: 18, and SEQ. ID NO: 19. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 18, SEQ. ID NO: 19, and SEQ. ID NO: 20. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 19, SEQ. ID NO: 20, and SEQ. ID NO: 21. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 20, SEQ. ID NO: 21, and SEQ. ID NO: 22. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 21, SEQ. ID NO: 22, and SEQ. ID NO: 23. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 22, SEQ. ID NO: 23, and SEQ. ID NO: 24. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 23, SEQ. ID NO: 24, and SEQ. ID NO: 25. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 24, SEQ. ID NO: 25, and SEQ. ID NO: 26. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 15, SEQ. ID NO: 16, SEQ. ID NO: 17, and SEQ ID NO: 18.

[0032] In embodiments, the F8 coding sequence comprises at least four consecutive exons selected from the group consisting of SEQ. ID NOs: 15 to 26 and optionally a portion of SEQ. ID NO: 14. In embodiments, the F8 coding sequence comprises the nucleotidesequences as set forth in SEQ. ID NO: 15, SEQ. ID NO: 16, SEQ. ID NO: 17, and SEQ. ID NO: 18. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 16, SEQ. ID NO: 17, SEQ. ID NO: 18, and SEQ. ID NO: 19. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 17, SEQ. ID NO: 18, SEQ. ID NO: 19, and SEQ. ID NO: 20. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 18, SEQ. ID NO: 19, SEQ. ID NO: 20, and SEQ. ID NO: 21. In embodiments, the F8 coding sequence compnses the nucleotide sequences as set forth in SEQ. ID NO: 19, SEQ. ID NO: 20, SEQ. ID NO: 21, and SEQ. ID NO: 22. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 20, SEQ. ID NO: 21, SEQ. ID NO: 22, and SEQ. ID NO: 23. In embodiments, the F8 coding sequence compnses the nucleotide sequences as set forth in SEQ. ID NO: 21, SEQ. ID NO: 22, SEQ. ID NO: 23, and SEQ. ID NO: 24. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 22, SEQ. ID NO: 23, SEQ. ID NO: 24, and SEQ. ID NO: 25. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 23, SEQ. ID NO: 24, SEQ. ID NO: 25, and SEQ. ID NO: 26.

[0033] In embodiments, the F8 coding sequence comprises at least five consecutive exons selected from the group consisting of SEQ. ID NOs: 15 to 26 and optionally a portion of SEQ. ID NO: 14. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 15, SEQ. ID NO: 16, SEQ. ID NO: 17, SEQ. ID NO:18, and SEQ. ID NO: 19. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 16, SEQ. ID NO: 17, SEQ. ID NO: 18, SEQ. ID NO:19, and SEQ. ID NO: 20. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 17, SEQ. ID NO: 18, SEQ. ID NO: 19, SEQ. ID NO:20, and SEQ. ID NO: 21. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 18, SEQ. ID NO: 19, SEQ. ID NO: 20, SEQ. ID NO:21, and SEQ. ID NO: 22. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 19, SEQ. ID NO: 20, SEQ. ID NO: 21, SEQ. ID NO:22, and SEQ. ID NO: 23. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 20, SEQ. ID NO: 21, SEQ. ID NO: 22, SEQ. ID NO:23, and SEQ. ID NO: 24. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 21, SEQ. ID NO: 22, SEQ. ID NO: 23, SEQ. ID NO:24, and SEQ. ID NO: 25. In embodiments, the F8 coding sequence comprises the nucleotidesequences as set forth in SEQ. ID NO: 22, SEQ. ID NO: 23, SEQ. ID NO: 24, SEQ. ID NO: 25, and SEQ. ID NO: 26.

[0034] In embodiments, the F8 coding sequence comprises at least six consecutive exons selected from the group consisting of SEQ. ID NOs: 15 to 26 and optionally a portion of SEQ. ID NO: 14. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 15, SEQ. ID NO: 16, SEQ. ID NO: 17, SEQ. ID NO: 18, SEQ. ID NO: 19, and SEQ. ID NO: 20. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 16, SEQ. ID NO: 17, SEQ. ID NO: 18, SEQ. ID NO: 19, SEQ. ID NO: 20, and SEQ. ID NO: 21. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 17, SEQ. ID NO: 18, SEQ. ID NO: 19, SEQ. ID NO: 20, SEQ. ID NO: 21, and SEQ. ID NO: 22. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 18, SEQ. ID NO: 19, SEQ. ID NO: 20, SEQ. ID NO: 21, SEQ. ID NO: 22, and SEQ. ID NO: 23. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 19, SEQ. ID NO: 20, SEQ. ID NO: 21, SEQ. ID NO: 22, SEQ. ID NO: 23, and SEQ. ID NO: 24. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 20, SEQ. ID NO: 21, SEQ. ID NO: 22, SEQ. ID NO: 23, SEQ. ID NO: 24, and SEQ. ID NO: 25. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 21, SEQ. ID NO: 22, SEQ. ID NO: 23, SEQ. ID NO: 24, SEQ. ID NO: 25, and SEQ. ID NO: 26.

[0035] In embodiments, the N' coding sequence comprises at least seven consecutive exons selected from the group consisting of SEQ. ID NOs: 15 to 26 and optionally a portion of SEQ. ID NO: 14. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 15, SEQ. ID NO: 16, SEQ. ID NO: 17, SEQ. ID NO: 18, SEQ. ID NO: 19, SEQ. ID NO: 20, and SEQ. ID NO: 21. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 16, SEQ. ID NO: 17, SEQ. ID NO: 18, SEQ. ID NO: 19, SEQ. ID NO: 20, SEQ. ID NO: 21, and SEQ. ID NO: 22. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 17, SEQ. ID NO: 18, SEQ. ID NO: 19, SEQ. ID NO: 20, SEQ. ID NO: 21, SEQ. ID NO: 22, and SEQ. ID NO: 23. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 18, SEQ. ID NO: 19, SEQ. ID NO: 20, SEQ. ID NO: 21, SEQ. ID NO: 22, SEQ. ID NO: 23, and SEQ ID NO: 24. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 19,SEQ. ID NO: 20, SEQ. ID NO: 21, SEQ. ID NO: 22, SEQ. ID NO: 23, SEQ. ID NO: 24, and SEQ. ID NO: 25. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 20, SEQ. ID NO: 21, SEQ. ID NO: 22, SEQ. ID NO: 23, SEQ. ID NO: 24, SEQ. ID NO: 25, and SEQ. ID NO: 26.

[0036] In embodiments, the F8 coding sequence comprises at least eight consecutive exons selected from the group consisting of SEQ. ID NOs: 15 to 26 and optionally a portion of SEQ. ID NO: 14. In some embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 15, SEQ. ID NO: 16, SEQ. ID NO: 17, SEQ. ID NO: 18, SEQ ID NO: 19, SEQ. ID NO: 20, SEQ. ID NO: 21, and SEQ. ID NO: 22. In some embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 16, SEQ. ID NO: 17, SEQ. ID NO: 18, SEQ. ID NO: 19, SEQ. ID NO: 20, SEQ. ID NO: 21, SEQ. ID NO: 22, and SEQ. ID NO: 23. In some embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 17, SEQ. ID NO: 18, SEQ. ID NO: 19, SEQ. ID NO: 20, SEQ. ID NO: 21, SEQ. ID NO: 22, SEQ. ID NO: 23, and SEQ. ID NO: 24. In some embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 18, SEQ. ID NO: 19, SEQ. ID NO: 20, SEQ. ID NO: 21, SEQ. ID NO: 22, SEQ. ID NO: 23, SEQ. ID NO: 24, and SEQ. ID NO: 25. In some embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 19, SEQ. ID NO: 20, SEQ. ID NO: 21, SEQ ID NO: 22, SEQ. ID NO: 23, SEQ ID NO: 24, SEQ. ID NO: 25, and SEQ. ID NO: 26.

[0037] In embodiments, the F8 coding sequence comprises at least nine consecutive exons selected from the group consisting of SEQ. ID NOs: 15 to 26 and optionally a portion of SEQ. ID NO: 14. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 15, SEQ. ID NO: 16, SEQ. ID NO: 17, SEQ. ID NO: 18, SEQ ID NO: 19, SEQ. ID NO: 20, SEQ. ID NO: 21, SEQ. ID NO: 22, and SEQ. ID NO: 23. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 16, SEQ. ID NO: 17, SEQ. ID NO: 18, SEQ. ID NO: 19, SEQ. ID NO: 20, SEQ. ID NO: 21, SEQ. ID NO: 22, SEQ. ID NO: 23, and SEQ. ID NO: 24. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 17, SEQ. ID NO: 18, SEQ. ID NO: 19, SEQ. ID NO: 20, SEQ. ID NO: 21, SEQ. ID NO: 22, SEQ. ID NO: 23, SEQ. ID NO: 24, and SEQ. ID NO: 25. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 18, SEQ. ID NO:19, SEQ ID NO: 20, SEQ. ID NO: 21, SEQ. ID NO: 22, SEQ. ID NO: 23, SEQ ID NO: 24, SEQ. ID NO: 25, and SEQ. ID NO: 26.

[0038] In embodiments, the F8 coding sequence comprises at least ten consecutive exons selected from the group consisting of SEQ. ID NOs: 15 to 26 and optionally a portion of SEQ. ID NO: 14. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 15, SEQ. ID NO: 16, SEQ. ID NO: 17, SEQ. ID NO:18, SEQ ID NO: 19, SEQ. ID NO: 20, SEQ. ID NO: 21, SEQ. ID NO: 22, SEQ ID NO: 23, and SEQ. ID NO: 24. In embodiments, the F8 coding sequence comprises the nucleotide sequences as set forth in SEQ. ID NO: 16, SEQ. ID NO: 17, SEQ. ID NO: 18, SEQ. ID NO:19, SEQ ID NO: 20, SEQ. ID NO: 21, SEQ. ID NO: 22, SEQ. ID NO: 23, SEQ ID NO: 24, and SEQ. ID NO: 25.

[0039] In embodiments, the N’ coding sequence comprises at least eleven consecutive exons selected from the group consisting of SEQ. ID NOs: 15 to 26 and optionally a portion of SEQ. ID NO: 14.

[0040] In embodiments, the 74? coding sequence comprises SEQ. ID NO: 15, SEQ. ID NO: 16, SEQ. ID NO: 17, SEQ. ID NO: 18, SEQ. ID NO: 19, SEQ. ID NO: 20, SEQ. ID NO: 21, SEQ. ID NO: 22, SEQ. ID NO: 23, SEQ. ID NO: 24, and SEQ. ID NO: 25.

[0041] In embodiments, the 5' homology arm nucleotide sequence consists of at least 200 contiguous nucleotide sequences within SEQ. ID NO: 1. In embodiments, the 5' homology arm nucleotide sequence consists of at least 300 contiguous nucleotide sequences within SEQ. ID NO: 62. In embodiments, the 5' homology arm nucleotide sequence consists of at least 400 contiguous nucleotide sequences within SEQ. ID NO: 62. In embodiments, the 5' homology arm nucleotide sequence consists of at least 500 contiguous nucleotide sequences within SEQ. ID NO: 62. In embodiments, the 5' homology arm nucleotide sequence consists of at least 600 contiguous nucleotide sequences within SEQ. ID NO: 62. In embodiments, the 5' homology arm nucleotide sequence consists of at least 700 contiguous nucleotide sequences within SEQ. ID NO: 62. In embodiments, the 5' homology arm nucleotide sequence consists of at least 800 contiguous nucleotide sequences within SEQ. ID NO: 62. In embodiments, the 5' homology arm nucleotide sequence consists of at least 900 contiguous nucleotide sequences within SEQ. ID NO: 62. In embodiments, the 5' homology arm nucleotide sequence consists of at least 1000 contiguous nucleotide sequences within SEQ. ID NO: 62. In embodiments, the 5' homology arm nucleotide sequence consists of at least1100 contiguous nucleotide sequences within SEQ. ID NO: 62. In embodiments, the 5' homology arm nucleotide sequence consists of at least 1200 contiguous nucleotide sequences within SEQ. ID NO: 62. In embodiments, the 5' homology arm nucleotide sequence consists of at least 1300 contiguous nucleotide sequences within SEQ. ID NO: 62. In embodiments, the 5' homology arm nucleotide sequence consists of at least 1400 contiguous nucleotide sequences within SEQ. ID NO: 62. In embodiments, the 5' homolog}7arm nucleotide sequence consists of at least 1500 contiguous nucleotide sequences within SEQ. ID NO: 62. In embodiments, the 5' homology arm nucleotide sequence consists of at least 1600 contiguous nucleotide sequences within SEQ. ID NO: 62. In embodiments, the 5' homology arm nucleotide sequence consists of at least 1700 contiguous nucleotide sequences within SEQ. ID NO: 62. In embodiments, the 5' homology arm nucleotide sequence consists of at least 1800 contiguous nucleotide sequences within SEQ. ID NO: 62. In embodiments, the 5' homology arm nucleotide sequence consists of at least 1900 contiguous nucleotide sequences within SEQ. ID NO: 62.

[0042] In embodiments, the 3' homology arm nucleotide sequence consists of at least 200 contiguous nucleotide sequences within SEQ. ID NO: 63. In embodiments, the 3' homology arm nucleotide sequence consists of at least 300 contiguous nucleotide sequences within SEQ. ID NO: 63. In embodiments, the 3' homology arm nucleotide sequence consists of at least 400 contiguous nucleotide sequences within SEQ. ID NO: 63. In embodiments, the 3' homology arm nucleotide sequence consists of at least 500 contiguous nucleotide sequences within SEQ. ID NO: 63. In embodiments, the 3' homology arm nucleotide sequence consists of at least 600 contiguous nucleotide sequences within SEQ. ID NO: 63. In embodiments, the 3' homology arm nucleotide sequence consists of at least 700 contiguous nucleotide sequences within SEQ. ID NO: 63. In embodiments, the 3' homology7arm nucleotide sequence consists of at least 800 contiguous nucleotide sequences within SEQ. ID NO: 63. In embodiments, the 3' homology arm nucleotide sequence consists of at least 900 contiguous nucleotide sequences within SEQ. ID NO: 63. In embodiments, the 3' homology arm nucleotide sequence consists of at least 1000 contiguous nucleotide sequences within SEQ. ID NO: 63. In embodiments, the 3' homology arm nucleotide sequence consists of at least 1100 contiguous nucleotide sequences within SEQ. ID NO: 63. In embodiments, the 3' homology arm nucleotide sequence consists of at least 1200 contiguous nucleotide sequences within SEQ. ID NO: 63. In embodiments, the 3' homology arm nucleotide sequence consists of at least 1300 contiguous nucleotide sequences within SEQ. ID NO: 63. In embodiments,the 3' homology arm nucleotide sequence consists of at least 1400 contiguous nucleotide sequences within SEQ. ID NO: 63. In embodiments, the 3' homology arm nucleotide sequence consists of at least 1500 contiguous nucleotide sequences within SEQ. ID NO: 63. In embodiments, the 3' homology arm nucleotide sequence consists of at least 1600 contiguous nucleotide sequences within SEQ. ID NO: 63. In embodiments, the 3' homology arm nucleotide sequence consists of at least 1700 contiguous nucleotide sequences within SEQ. ID NO: 63. In embodiments, the 3' homology arm nucleotide sequence consists of at least 1800 contiguous nucleotide sequences within SEQ. ID NO: 63. In embodiments, the 3' homology arm nucleotide sequence consists of at least 1900 contiguous nucleotide sequences within SEQ. ID NO: 63.

[0043] In embodiments, the 5' homology arm nucleotide sequence consists of at least 200 contiguous nucleotide sequences within SEQ. ID NO: 64. In embodiments, the 5' homology arm nucleotide sequence consists of at least 300 contiguous nucleotide sequences within SEQ. ID NO: 64. In embodiments, the 5' homology arm nucleotide sequence consists of at least 400 contiguous nucleotide sequences within SEQ. ID NO: 64. In embodiments, the 5' homology arm nucleotide sequence consists of at least 500 contiguous nucleotide sequences within SEQ. ID NO: 64. In embodiments, the 5' homology arm nucleotide sequence consists of at least 600 contiguous nucleotide sequences within SEQ. ID NO: 64. In embodiments, the 5' homology arm nucleotide sequence consists of at least 700 contiguous nucleotide sequences within SEQ. ID NO: 64. In embodiments, the 5' homology arm nucleotide sequence consists of at least 800 contiguous nucleotide sequences within SEQ. ID NO: 64. In embodiments, the 5' homology arm nucleotide sequence consists of at least 900 contiguous nucleotide sequences within SEQ. ID NO: 64. In embodiments, the 5' homology arm nucleotide sequence consists of at least 1000 contiguous nucleotide sequences within SEQ. ID NO: 64. In embodiments, the 5' homology arm nucleotide sequence consists of at least 1100 contiguous nucleotide sequences within SEQ. ID NO: 64. In embodiments, the 5' homology arm nucleotide sequence consists of at least 1200 contiguous nucleotide sequences within SEQ. ID NO: 64. In embodiments, the 5' homology arm nucleotide sequence consists of at least 1300 contiguous nucleotide sequences within SEQ. ID NO: 64. In embodiments, the 5' homology arm nucleotide sequence consists of at least 1400 contiguous nucleotide sequences within SEQ. ID NO: 64. In embodiments, the 5' homology arm nucleotide sequence consists of at least 1500 contiguous nucleotide sequences within SEQ. ID NO: 64. In embodiments, the 5' homology arm nucleotide sequence consists of at least 1600contiguous nucleotide sequences within SEQ. ID NO: 64. In embodiments, the 5' homology arm nucleotide sequence consists of at least 1700 contiguous nucleotide sequences within SEQ. ID NO: 64. In embodiments, the 5' homology arm nucleotide sequence consists of at least 1800 contiguous nucleotide sequences within SEQ. ID NO: 64. In embodiments, the 5' homology arm nucleotide sequence consists of at least 1900 contiguous nucleotide sequences within SEQ. ID NO: 64.

[0044] In embodiments, the 3' homology arm nucleotide sequence consists of at least 200 contiguous nucleotide sequences within SEQ. ID NO: 65. In embodiments, the 3' homology arm nucleotide sequence consists of at least 300 contiguous nucleotide sequences within SEQ. ID NO: 65. In embodiments, the 3' homology arm nucleotide sequence consists of at least 400 contiguous nucleotide sequences within SEQ. ID NO: 65. In embodiments, the 3' homology arm nucleotide sequence consists of at least 500 contiguous nucleotide sequences within SEQ. ID NO: 65. In embodiments, the 3' homology arm nucleotide sequence consists of at least 600 contiguous nucleotide sequences within SEQ. ID NO: 65. In embodiments, the 3' homology arm nucleotide sequence consists of at least 700 contiguous nucleotide sequences within SEQ. ID NO: 65. In embodiments, the 3' homolog}7arm nucleotide sequence consists of at least 800 contiguous nucleotide sequences within SEQ. ID NO: 65. In embodiments, the 3' homology arm nucleotide sequence consists of at least 900 contiguous nucleotide sequences within SEQ. ID NO: 65. In embodiments, the 3' homology arm nucleotide sequence consists of at least 1000 contiguous nucleotide sequences within SEQ. ID NO: 65. In embodiments, the 3' homology arm nucleotide sequence consists of at least 1100 contiguous nucleotide sequences within SEQ. ID NO: 65. In embodiments, the 3' homology arm nucleotide sequence consists of at least 1200 contiguous nucleotide sequences within SEQ. ID NO: 65. In embodiments, the 3' homology arm nucleotide sequence consists of at least 1300 contiguous nucleotide sequences within SEQ. ID NO: 65. In embodiments, the 3' homology arm nucleotide sequence consists of at least 1400 contiguous nucleotide sequences within SEQ. ID NO: 65. In embodiments, the 3' homolog}7arm nucleotide sequence consists of at least 1500 contiguous nucleotide sequences within SEQ. ID NO: 65. In embodiments, the 3' homology arm nucleotide sequence consists of at least 1600 contiguous nucleotide sequences within SEQ. ID NO: 65. In embodiments, the 3' homology arm nucleotide sequence consists of at least 1700 contiguous nucleotide sequences within SEQ. ID NO: 65. In embodiments, the 3' homology arm nucleotide sequence consists of at least 1800 contiguous nucleotide sequences within SEQ. ID NO: 65. In embodiments, the 3'homology arm nucleotide sequence consists of at least 1900 contiguous nucleotide sequences within SEQ. ID NO: 65.

[0045] In embodiments, the 5' homology arm nucleotide sequence consists of at least 200 contiguous nucleotide sequences within SEQ. ID NO: 66. In embodiments, the 5' homology arm nucleotide sequence consists of at least 300 contiguous nucleotide sequences within SEQ. ID NO: 66. In embodiments, the 5' homology arm nucleotide sequence consists of at least 400 contiguous nucleotide sequences within SEQ. ID NO: 66. In embodiments, the 5' homology arm nucleotide sequence consists of at least 500 contiguous nucleotide sequences within SEQ. ID NO: 66. In embodiments, the 5' homology arm nucleotide sequence consists of at least 600 contiguous nucleotide sequences within SEQ. ID NO: 66. In embodiments, the 5' homology arm nucleotide sequence consists of at least 700 contiguous nucleotide sequences within SEQ. ID NO: 66. In embodiments, the 5' homology arm nucleotide sequence consists of at least 800 contiguous nucleotide sequences within SEQ. ID NO: 66. In embodiments, the 5' homology arm nucleotide sequence consists of at least 900 contiguous nucleotide sequences within SEQ. ID NO: 66. In embodiments, the 5' homology arm nucleotide sequence consists of at least 1000 contiguous nucleotide sequences within SEQ. ID NO: 66. In embodiments, the 5' homology arm nucleotide sequence consists of at least 1100 contiguous nucleotide sequences within SEQ. ID NO: 66. In embodiments, the 5' homology arm nucleotide sequence consists of at least 1200 contiguous nucleotide sequences within SEQ. ID NO: 66. In embodiments, the 5' homology arm nucleotide sequence consists of at least 1300 contiguous nucleotide sequences within SEQ. ID NO: 66. In embodiments, the 5' homology arm nucleotide sequence consists of at least 1400 contiguous nucleotide sequences within SEQ. ID NO: 66. In embodiments, the 5' homology' arm nucleotide sequence consists of at least 1500 contiguous nucleotide sequences within SEQ. ID NO: 66. In embodiments, the 5' homology arm nucleotide sequence consists of at least 1600 contiguous nucleotide sequences within SEQ. ID NO: 66. In embodiments, the 5' homology arm nucleotide sequence consists of at least 1700 contiguous nucleotide sequences within SEQ. ID NO: 66. In embodiments, the 5' homology arm nucleotide sequence consists of at least 1800 contiguous nucleotide sequences within SEQ. ID NO: 66. In embodiments, the 5' homology arm nucleotide sequence consists of at least 1900 contiguous nucleotide sequences within SEQ. ID NO: 66.

[0046] In embodiments, the 3' homology arm nucleotide sequence consists of at least 200 contiguous nucleotide sequences within SEQ. ID NO: 67. In embodiments, the 3' homologyarm nucleotide sequence consists of at least 300 contiguous nucleotide sequences within SEQ. ID NO: 67. In embodiments, the 3' homology arm nucleotide sequence consists of at least 400 contiguous nucleotide sequences within SEQ. ID NO: 67. In embodiments, the 3' homology arm nucleotide sequence consists of at least 500 contiguous nucleotide sequences within SEQ. ID NO: 67. In embodiments, the 3' homology arm nucleotide sequence consists of at least 600 contiguous nucleotide sequences within SEQ. ID NO: 67. In embodiments, the 3' homology arm nucleotide sequence consists of at least 700 contiguous nucleotide sequences within SEQ. ID NO: 67. In embodiments, the 3' homology arm nucleotide sequence consists of at least 800 contiguous nucleotide sequences within SEQ. ID NO: 67. In embodiments, the 3' homology arm nucleotide sequence consists of at least 900 contiguous nucleotide sequences within SEQ. ID NO: 67. In embodiments, the 3' homology arm nucleotide sequence consists of at least 1000 contiguous nucleotide sequences within SEQ. ID NO: 67. In embodiments, the 3' homology arm nucleotide sequence consists of at least 1100 contiguous nucleotide sequences within SEQ. ID NO: 67. In embodiments, the 3' homology arm nucleotide sequence consists of at least 1200 contiguous nucleotide sequences within SEQ. ID NO: 67. In embodiments, the 3' homology arm nucleotide sequence consists of at least 1300 contiguous nucleotide sequences within SEQ. ID NO: 67. In embodiments, the 3' homology arm nucleotide sequence consists of at least 1400 contiguous nucleotide sequences within SEQ. ID NO: 67. In embodiments, the 3' homology arm nucleotide sequence consists of at least 1500 contiguous nucleotide sequences within SEQ. ID NO: 67. In embodiments, the 3' homology arm nucleotide sequence consists of at least 1600 contiguous nucleotide sequences within SEQ. ID NO: 67. In embodiments, the 3' homology arm nucleotide sequence consists of at least 1700 contiguous nucleotide sequences within SEQ. ID NO: 67. In embodiments, the 3' homology arm nucleotide sequence consists of at least 1800 contiguous nucleotide sequences within SEQ. ID NO: 67. In embodiments, the 3' homology arm nucleotide sequence consists of at least 1900 contiguous nucleotide sequences within SEQ. ID NO: 67.

[0047] In embodiments, the correction genome does not include any F8 gene coding sequence other than the recited SEQ. ID NOs. herein for the editing element, the 5' homology arm, and the 3' homology arm. In embodiments, the replication-defective adeno-associated virus (AAV) comprising the AAV capsid and the correction genome, does not include any other F8 coding sequence other than the recited SEQ. ID NOS herein for the editing element, the 5' homology arm and the 3' homology arm.

[0048] These and other embodiments of the disclosure are provided in more detail herein.BRIEF DESCRIPTION OF THE DRAWINGS

[0049] FIG. 1 illustrates the genome editing strategy mapped on to the genomic and protein domain structure of the Factor 8 gene. Position of Exons (1-26) is shown. Protein structure shows different domains where different patterns represent the corresponding exons. Schema of 3 consecutively tiled F8 AAV editing vectors is shown aligned to the F8 gene and FVIII protein. “CO” is codon optimized.

[0050] FIG. 2 illustrates a schema of AAV F8 editing vectors. In the scheme, three consecutively tiled editing vectors were designed to edit Exons 2 to 13 (N-Ter), Exon 14 (CEN) and Exons 15 to 26 (C-Ter). The illustrated editing vectors were designed to insert a promoterless Venus ORF-pA cassette at the end of the correction cDNA. The level of Venus expression reflects the editing efficiency of the N-Ter, CEN & C-Ter vectors.

[0051] FIG. 3 illustrates a schema of AAV F8 correction vectors. In the figure, the N-Ter vector corrects mutations in Exons 2 to 13. The CEN vector corrects mutations in Exon 14. The C-Ter correction corrects mutations in Exons 15 to 26.

[0052] FIG. 4 illustrates the editing efficiency of N-Ter and C-Ter AAV F8 editing vectors in primary human cells. LSEC: N=3; Fibroblasts: N=2.

[0053] FIG. 5 illustrates the map of the N-ter editing vector for mutations in exons 2-13 of the F8 gene.

[0054] FIG. 6 illustrates the map of the CEN editing vector for mutations in exon 14 of the F8 gene.

[0055] FIG. 7 illustrates the map of the c-ter editing vector for mutations in exons 15-26 of the F8 geneDETAILED DESCRIPTION

[0056] Before the present invention is further described, it is to be understood that this invention is not strictly limited to particular embodiments described, as such may of course vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the claims.

[0057] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and / or materials in connection with which the publications are cited. The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates, which may need to be independently confirmed.

[0058] It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination. All combinations of the embodiments are specifically embraced by the present invention and are disclosed herein just as if each and every combination was individually and explicitly disclosed. In addition, all sub-combinations are also specifically embraced by the present invention and are disclosed herein just as if each and every such subcombination was individually and explicitly disclosed herein.

[0059] It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely ,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.I DEFINITIONS

[0060] As used herein, the term “about” means a range of values including the specified value, which a person of ordinary skill in the art would consider reasonably similar to the specified value. In embodiments, about means within a standard deviation using measurements generally acceptable in the art. In embodiments, about means a range extending to + / - 10% of the specified value. In embodiments, about means the specified value.

[0061] A “chemical linker,” as provided herein, is a covalent linker. In embodiments, the chemical linker is a bond, -O-, -S-, -C(O)-, -C(O)O-,-C(O)NH-, -S(O)2NH-, -NH-, - NHC(O)NH-, a substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene or substituted or unsubstituted heteroarylene or any combination thereof.

[0062] The chemical linker as provided herein may be a bond, -O-, -S-, -C(O)-, -C(O)O- , -C(O)NH-, -S(O)2NH-, -NH-, -NHC(O)NH-, substituted or unsubstituted (e.g., C1-C20, Ci- C10, C1-C5) alkylene, substituted or unsubstituted (e.g., 2 to 20 membered, 2 to 10 membered, 2 to 5 membered) heteroalkylene, substituted or unsubstituted (e.g., C3-C8, C3-C6, C3-C5) cycloalkylene, substituted or unsubstituted (e.g., 3 to 8 membered, 3 to 6 membered, 3 to 5 membered) heterocycloalkylene, substituted or unsubstituted (e.g., Ce-Cio, Ce-Cs, C6-C5) arylene or substituted or unsubstituted (e.g., 5 to 10 membered, 5 to 8 membered, 5 to 6 membered,) heteroarylene.

[0063] The term “amino acid” refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, y- carboxy glutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid. The terms “non-naturally occurring amino acid” and “unnatural amino acid” refer to amino acid analogs, synthetic amino acids, and amino acid mimetics which are not found in nature.

[0064] Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

[0065] The terms ‘‘polypeptide,” “peptide” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues, wherein the polymer may In embodiments be conjugated to a moiety that does not consist of amino acids. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers. A “fusion protein” refers to a chimeric protein encoding two or more separate protein sequences that are recombinantly expressed as a single moiety.

[0066] As may be used herein, the terms “nucleic acid,” “nucleic acid molecule,” “nucleic acid oligomer,” “oligonucleotide,” “nucleic acid sequence,” “nucleic acid fragment” and “polynucleotide” are used interchangeably and are intended to include, but are not limited to, a polymeric form of nucleotides covalently linked together that may have various lengths, either deoxyribonucleotides or ribonucleotides, or analogs, derivatives or modifications thereof. Different polynucleotides may have different three-dimensional structures, and may perform various functions, known or unknown. Non-limiting examples of polynucleotides include a gene, a gene fragment, an exon, an intron, intergenic DNA (including, without limitation, heterochromatic DNA), messenger RNA (mRNA), transfer RNA, ribosomal RNA, a ribozyme, cDNA, a recombinant polynucleotide, a branched polynucleotide, a plasmid, a vector, isolated DNA of a sequence, isolated RNA of a sequence, a nucleic acid probe, and a primer. Polynucleotides useful in the methods of the disclosure may comprise natural nucleic acid sequences and variants thereof, artificial nucleic acid sequences, or a combination of such sequences.

[0067] A polynucleotide is typically composed of a specific sequence of four nucleotide bases: adenine (A); cytosine (C); guanine (G); and thymine (T) (uracil (U) for thymine (T) when the polynucleotide is RNA). Thus, the term “polynucleotide sequence” is the alphabetical representation of a polynucleotide molecule; alternatively, the term may be applied to the polynucleotide molecule itself. This alphabetical representation can be input into databases in a computer having a central processing unit and used for bioinformatics applications such as functional genomics and homology searching. Polynucleotides may optionally include one or more non-standard nucleotide(s), nucleotide analog(s) and / or modified nucleotides.

[0068] Nucleic acids, including e.g., nucleic acids with a phosphothioate backbone, can include one or more reactive moieties. As used herein, the term reactive moiety includes any group capable of reacting with another molecule, e.g., a nucleic acid or polypeptide through covalent, non-covalent or other interactions. By way of example, the nucleic acid can include an amino acid reactive moiety that reacts with an amio acid on a protein or polypeptide through a covalent, non-covalent or other interaction.

[0069] The terms also encompass nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non- naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides. Examples of such analogs include, include, without limitation, phosphodiester derivatives including, e.g., phosphoramidate, phosphorodiamidate, phosphorothioate (also known as phosphorothioate having double bonded sulfur replacing oxygen in the phosphate), phosphorodithioate, phosphonocarboxylic acids, phosphonocarboxylates, phosphonoacetic acid, phosphonoformic acid, methyl phosphonate, boron phosphonate, or O-methylphosphoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press) as well as modifications to the nucleotide bases such as in 5-methyl cytidine or pseudouridine; and peptide nucleic acid backbones and linkages. Other analog nucleic acids include those with positive backbones; non-iomc backbones, modified sugars, and non-ribose backbones (e.g. phosphorodiamidate morpholino oligos or locked nucleic acids (LNA) as known in the art), including those described in U.S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, Carbohydrate Modifications in Antisense Research, Sanghui & Cook, eds. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids. Modifications of the nbose-phosphate backbone may be done for a variety of reasons, e.g., to increase the stability and half-life of such molecules in physiological environments or as probes on a biochip. Mixtures of naturally occurring nucleic acids and analogs can be made; alternatively, mixtures of different nucleic acid analogs, and mixtures of naturally occurring nucleic acids and analogs may be made. In aspects, the intemucleotide linkages in DNA are phosphodiester, phosphodiester derivatives, or a combination of both.

[0070] Nucleic acids can include nonspecific sequences. As used herein, the term “nonspecific sequence” refers to a nucleic acid sequence that contains a series of residues that are not designed to be complementary to or are only partially complementary to any othernucleic acid sequence. By way of example, a nonspecific nucleic acid sequence is a sequence of nucleic acid residues that does not function as an inhibitory nucleic acid when contacted with a cell or organism.

[0071] The term “complementary” or “complementarity” refers to the ability of a nucleic acid to form hydrogen bond(s) with another nucleic acid sequence by either traditional Watson-Crick or other non-traditional types. For example, the sequence A-G-T is complementary to the sequence T-C-A. A percent complementarity indicates the percentage of residues in a nucleic acid molecule which can form hydrogen bonds (e.g. , Watson-Cnck base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 out of 10 being 50%, 60%, 70%, 80%, 90%, and 100% complementary, respectively). “Perfectly complementary” means that all the contiguous residues of a nucleic acid sequence will hydrogen bond with the same number of contiguous residues in a second nucleic acid sequence. “Substantially complementary” as used herein refers to a degree of complementarity that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%. 97%, 98%, 99%, or 100% over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, or more nucleotides, or refers to two nucleic acids that hybridize under stringent conditions (i.e., stringent hybridization conditions)

[0072] The term “gene” means the segment of DNA involved in producing a protein; it includes regions preceding and following the coding region (leader and trailer) as well as intervening sequences (introns) between individual coding segments (exons). The leader, the trailer as well as the introns include regulatory elements that are necessary during the transcription and the translation of a gene. Further, a “protein gene product” is a protein expressed from a particular gene.

[0073] The word “expression” or “expressed” as used herein in reference to a gene means the transcriptional and / or translational product of that gene. The level of expression of a DNA molecule in a cell may be determined on the basis of either the amount of corresponding mRNA that is present within the cell or the amount of protein encoded by that DNA produced by the cell. The level of expression of non-coding nucleic acid molecules (e.g., sgRNA) may be detected by standard PCR or Northern blot methods well known in the art. See, Sambrook et al., 1989 Molecular Cloning: A Laboratory Manual, 18.1-18.88.

[0074] The term “amino acid” refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to thenaturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxy proline, y- carboxy glutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.

[0075] Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

[0076] The terms “polypeptide,” “peptide” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer.

[0077] The term “exon” as used herein refers to refers to the sequence of DNA present in mature messenger RNA (mRNA), some of which encodes the amino acids of a protein. In embodiments, the F8 gene contains 26 exons with introns between them.

[0078] The term “consecutive” in the context of “consecutive exons” refers to the exons that are next to each other despite introns that are in between them. For example, Exon 2 and Exon 3; Exon 3 and Exon 4; Exon 4 and Exon 5 are considered consecutive exons. Similarly, Exon 2, Exon 3, and Exon 4 are consecutive exons, whereas Exon 2, Exon 3, and Exon 5 are not consecutive exons.

[0079] An amino acid or nucleotide base “position” is denoted by a number that sequentially identifies each amino acid (or nucleotide base) in the reference sequence based on its position relative to the N-terminus (or 5'-end). Due to deletions, insertions, truncations, fusions, and the like that may be taken into account when determining an optimal alignment,in general the amino acid residue number in a test sequence determined by simply counting from the N-terminus will not necessarily be the same as the number of its corresponding position in the reference sequence. For example, in a case where a variant has a deletion relative to an aligned reference sequence, there will be no amino acid in the variant that corresponds to a position in the reference sequence at the site of deletion. Where there is an insertion in an aligned reference sequence, that insertion will not correspond to a numbered amino acid position in the reference sequence. In the case of truncations or fusions there can be stretches of ammo acids in either the reference or aligned sequence that do not correspond to any amino acid in the corresponding sequence.

[0080] The terms “numbered with reference to” or “corresponding to,” when used in the context of the numbering of a given ammo acid or polynucleotide sequence, refers to the numbering of the residues of a specified reference sequence when the given amino acid or polynucleotide sequence is compared to the reference sequence. An amino acid residue in a protein “corresponds” to a given residue when it occupies the same essential structural position within the protein as the given residue.

[0081] “Conservatively modified variants” applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, “conservatively modified variants” refers to those nucleic acids that encode identical or essentially identical amino acid sequences. Because of the degeneracy of the genetic code, a number of nucleic acid sequences will encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are “silent variations,” which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in each described sequence.

[0082] As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence whichalters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a ‘"conservatively modified variant” where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the disclosure.

[0083] The following eight groups each contain amino acids that are conservative substitutions for one another:1) Alanine (A), Glycine (G);2) Aspartic acid (D), Glutamic acid (E);3) Asparagine (N), Glutamine (Q);4) Arginine (R), Lysine (K);5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V);6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W);7) Serine (S), Threonine (T); and8) Cysteine (C), Methionine (M)(see, e.g., Creighton, Proteins (1984)).

[0084] “Percentage of sequence identity” is determined by comparing two optimally aligned sequences over a comparison window; wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (z.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.

[0085] The terms “identical” or percent “identity,” in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same(i.e., about 60% identity, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (see, e.g, NCBI web site http: / / www.ncbi.nlm.nih.gov / BLAST / or the like). Such sequences are then said to be “substantially identical.” This definition also refers to, or may be applied to, the compliment of a test sequence. The definition also includes sequences that have deletions and / or additions, as well as those that have substitutions. As described below, the preferred algorithms can account for gaps and the like. Preferably, identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 amino acids or nucleotides in length.

[0086] For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

[0087] A “comparison window”, as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of, e.g., a full length sequence or from 20 to 600, about 50 to about 200, or about 100 to about 150 amino acids or nucleotides in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman (1970) Adv. Appl. Math. 2:482c, by the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443, by the search for similarity method of Pearson and Lipman (UA ) Proc. Nat ’I. Acad. Sei. USA 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, e.g., Ausubel et al., Current Protocols in Molecular Biology (1995 supplement)).

[0088] An amino acid or nucleotide base “position” is denoted by a number that sequentially identifies each amino acid (or nucleotide base) in the reference sequence based on its position relative to the N-terminus (or 5'-end). Due to deletions, insertions, truncations, fusions, and the like that must be taken into account when determining an optimal alignment, in general the amino acid residue number in a test sequence determined by simply counting from the N-terminus will not necessarily be the same as the number of its corresponding position in the reference sequence. For example, in a case where a variant has a deletion relative to an aligned reference sequence, there will be no amino acid in the variant that corresponds to a position in the reference sequence at the site of deletion. Where there is an insertion in an aligned reference sequence, that insertion will not correspond to a numbered amino acid position in the reference sequence. In the case of truncations or fusions there can be stretches of ammo acids in either the reference or aligned sequence that do not correspond to any amino acid in the corresponding sequence.

[0089] The terms “numbered with reference to” or “corresponding to,” when used in the context of the numbering of a given amino acid or polynucleotide sequence, refers to the numbering of the residues of a specified reference sequence when the given amino acid or polynucleotide sequence is compared to the reference sequence.

[0090] The term “non-natural amino acid side chain” refers to the functional substituent of compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium, allylalanine, 2-aminoisobutryric acid. Non-natural amino acids are non-proteinogenic amino acids that either occur naturally or are chemically synthesized. Such analogs have modified R groups (e.g, norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Non-limiting examples include exo-cis-3- Aminobicyclo[2.2.1]hept-5-ene-2-carboxylic acid hydrochloride, cis-2- Aminocycloheptanecarboxylic acid hydrochloride, cis-6-Amino-3-cyclohexene-l-carboxylic acid hydrochloride, cis-2-Amino-2-methylcyclohexanecarboxylic acid hydrochloride, cis-2- Amino-2 -methylcyclopentanecarboxy lie acid hydrochloride, 2-(Boc-aminomethyl)benzoic acid, 2-(Boc-amino)octanedioic acid, Boc-4,5-dehydro-Leu-OH (dicyclohexylammomum), Boc-4-(Fmoc-amino)-L-phenylalanine, Boc- -Homopyr-OH, Boc-(2-indanyl)-Gly-OH , 4- Boc-3-morpholineacetic acid, 4-Boc-3-morpholineacetic acid , Boc-pentafluoro-D- phenylalanine, Boc-pentafluoro-L-phenylalanine , Boc-Phe(2-Br)-OH, Boc-Phe(4-Br)-OH,Boc-D-Phe(4-Br)-OH, Boc-D-Phe(3-Cl)-OH , Boc-Phe(4-NH2)-OH, Boc-Phe(3-NO2)-OH, Boc-Phe(3,5-F2)-OH, 2-(4-Boc-piperazino)-2-(3,4-dimethoxyphenyl)acetic acid purum, 2-(4- Boc-piperazino)-2-(2-fluorophenyl)acetic acid purum, 2-(4-Boc-piperazino)-2-(3- fluorophenyl)acetic acid purum, 2-(4-Boc-piperazino)-2-(4-fluorophenyl)acetic acid purum, 2-(4-Boc-piperazino)-2-(4-methoxyphenyl)acetic acid purum, 2-(4-Boc-piperazino)-2- phenylacetic acid purum, 2-(4-Boc-piperazino)-2-(3-pyridyl)acetic acid purum, 2-(4-Boc- piperazino)-2-[4-(trifluoromethyl)phenyl]acetic acid purum, Boc-P-(2-quinolyl)-Ala-OH, N- Boc-l,2,3,6-tetrahydro-2-pyridinecarboxylic acid, Boc-P-(4-thiazolyl)-Ala-OH, Boc-P-(2- thienyl)-D-Ala-OH, Fmoc-N-(4-Boc-aminobutyl)-Gly-OH, Fmoc-N-(2-Boc-aminoethyl)- Gly-OH , Fmoc-N-(2,4-dimethoxybenzyl)-Gly-OH, Fmoc-(2-indanyl)-Gly-OH, Fmoc- pentafluoro-L-phenylalanine, Fmoc-Pen(Trt)-OH, Fmoc-Phe(2-Br)-OH, Fmoc-Phe(4-Br)- OH, Fmoc-Phe(3,5-F2)-OH, Fmoc-P-(4-thiazolyl)-Ala-OH, Fmoc-P-(2-thienyl)-Ala-OH, 4- (Hydroxymethyl)-D-phenylalanine.

[0091] The term “contacting” may include allowing two species to react, interact, or physically touch, wherein the two species may be a compound as described herein and a protein or enzyme. In some embodiments contacting includes allowing a compound described herein to interact with a protein or enzyme that is involved in a signaling pathway.

[0092] The term “expression” includes any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion. Expression can be detected using conventional techniques for detecting protein (e.g. , ELISA, Western blotting, flow cytometry, immunofluorescence, immunohistochemistry, etc.).

[0093] The term “modulator” refers to a composition that increases or decreases the level of a target molecule or the function of a target molecule or the physical state of the target of the molecule relative to the absence of the modulator.

[0094] The term “modulate” is used in accordance with its plain ordinary meaning and refers to the act of changing or varying one or more properties. “Modulation” refers to the process of changing or varying one or more properties. For example, as applied to the effects of a modulator on a target protein, to modulate means to change by increasing or decreasing a property or function of the target molecule or the amount of the target molecule.

[0095] The term “associated” or “associated with” in the context of a substance or substance activity or function associated with a disease (e.g. a protein associated disease, a cancer (e.g., cancer, inflammatory disease, autoimmune disease, or infectious disease)) means that the disease (e.g. cancer, inflammatory disease, autoimmune disease, or infectious disease) is caused by (in whole or in part), or a symptom of the disease is caused by (in whole or in part) the substance or substance activity or function. As used herein, what is described as being associated with a disease, if a causative agent, could be a target for treatment of the disease.

[0096] The term “signaling pathway” as used herein refers to a series of interactions between cellular and optionally extra-cellular components (e.g. proteins, nucleic acids, small molecules, ions, lipids) that conveys a change in one component to one or more other components, which in turn may convey a change to additional components, which is optionally propagated to other signaling pathway components.

[0097] As used herein, the term “replication-defective adeno-associated virus” refers to an AAV comprising a genome lacking Rep and Cap genes.

[0098] As used herein, the term “F5 gene” refers to a recombinant or naturally-occurring forms encoding the FVIII protein or variants or homologs thereof that maintain FVIII protein activity (e.g. within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity7compared to FVIII protein). The F8 gene includes, but not limited to, the coding regions, exons, introns, 5' UTR, 3' UTR, and transcriptional regulatory regions of the F8 gene. In some aspects, the variants or homologs have at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity across the whole sequence or a portion of the sequence (e.g. a 50, 100, 150 or 200 continuous amino acid portion) compared to a naturally occurring F8 gene. The human F8 gene is identified by Entrez Gene ID 2157. Naturally occurring or wild-ty pe human FS gene is identified by nucleotides 5,001 to 191,936 ofNCBI Reference Sequence: NG_011403.2. An exemplary nucleotide sequence of a full-length human F8 cDNA is identified by NCBI Reference No.: NM_000132.4. An exemplary amino acid sequence of a full-length human FVIII polypeptide, including its 19-amino acid signal peptide, is identified by NCBI Reference No.: NP_000123.1.

[0099] As used herein, the term “homology arms” is used in accordance with its plain and orfmary meaning and refers to nuceliec acid sequences that are designed to align the correction genome to the specific target location withinthe F8 gene. Homology arms can bedirected to any region of the F8 gene or a gene nearby on the genome. In embodiments, the correction genome comprises homology' arms. In embodiments, the exact identity and positioning of the homology arms are determined by the identity of the editing element and / or the target locus. In embodiments, the homology arms comprise one or more genetic variations in the human population. In embodiments, the homology' arms comprise one or more modifications (e.g., nucleotide substitutions, insertions, or deletions) designed to improve expression level or specificity. In embodiments, the homology arms comprise one or more genetic variations and optionally one more modification designed to improve expression level or specificity in the human population. In embodiments, human genetic variations may include both inherited variations and de novo variations that are particular to the target genome, and encompass insertions, deletions, simple nucleotide polymorphisms, inversions, rearrangements, inversions, micro-repeats, and combinations thereof.

[0100] As used herein, the term “correcting a mutation in an F8 gene” refers to the insertion, deletion, or substitution of one or more nucleotides at a target locus in a mutant F8 gene to create an F8 gene that is capable of expressing a wild-type FVIII polypeptide or a functional equivalent thereof. In certain embodiments, “correcting a mutation in an F8 gene” involves inserting a nucleotide sequence encoding at least a portion of a wild-type FVIII polypeptide or a functional equivalent thereof into the mutant F8 gene, such that a wild-type FVIII polypeptide or a functional equivalent thereof is expressed from the mutant F8 gene locus (e.g., under the control of an endogenous F8 gene promoter). A skilled person in the art will appreciate that the portion of a correction genome comprising the 5' homology arm, editing element, and 3' homology arm can be in the sense or antisense orientation relative to the target locus (e.g. , the human F8 gene).

[0101] As used herein, the term “correction genome” refers to a recombinant AAV genome that is capable of integrating an editing element (e.g., one or more nucleotides or an intemucleotide bond) via homologous recombination into a target locus to correct a genetic defect in an F8 gene. In certain embodiments, the target locus is in the human F8 gene. The skilled artisan will appreciate that the portion of a correction genome comprising the 5' homology arm, editing element, and 3' homology arm can be in the sense or antisense orientation relative to the target locus (e.g. , the human F8 gene).

[0102] As used herein, the term “editing element” refers to the portion of a correction genome that when integrated at a target locus modifies the target locus. An editing element can mediate insertion, deletion, or substitution of one or more nucleotides at the target locus.

[0103] As used herein, the term “target locus” refers to a region of a chromosome or an intemucleotide bond (e.g., a region or an intemucleotide bond of the human F8 gene) that is modified by an editing element.

[0104] As used herein, the term “a disease or disorder associated with an F8 gene mutation” refers to any disease or disorder caused by, exacerbated by, or genetically linked with mutation of an F8 gene. The F8 protein is an essential blood-clotting protein. In certain embodiments, the disease or disorder associated with an F8 gene mutation is hemophilia A.

[0105] As used herein, the term “coding sequence” refers to the portion of a complementary DNA (cDNA) that encodes a polypeptide, starting at the start codon and ending at the stop codon. A gene may have one or more coding sequences due to alternative splicing and / or alternative translation initiation. A coding sequence may either be wild-type or silently altered. An exemplary full-length wild-type F8 coding sequence is identified by nucleotides 172 to 7,227 of NCBI Reference No.: NM_000132.4. An exemplary portion of wild-type F8 coding sequence, corresponding to exons 2 to 13, exon 14, or exons 15 to 26.

[0106] As used herein, the term “silently altered” or “silent alteration” refers to alteration of a coding sequence of a gene (e.g., by nucleotide substitution) without changing the amino acid sequence of the polypeptide encoded by the gene. In certain embodiments, silent alteration increases the expression level of a coding sequence. In certain embodiments, silent alteration reduces off-targeting to undesired genomic loci.

[0107] As used herein, the term “polyadenylation sequence” refers to a DNA sequence that when transcribed into RNA constitutes a polyadenylation signal sequence. The polyadenylation sequence can be native (e.g., from the F8 gene) or exogenous. The exogenous polyadenylalion sequence can be a mammalian or a viral polyadenylation sequence (e.g., an SV40 polyadenylation sequence).

[0108] As used herein, the term “integration” refers to introduction of an editing element into a target locus of a target gene by homologous recombination between a correction genome and the target gene. Integration of an editing element can result in substitution, insertion and / or deletion of one or more nucleotides in a target gene. For example, in certainembodiments, the term “integration” refers to introduction of an editing element into a target locus of an F8 gene by homologous recombination between a correction genome and the F8 gene. Integration of an editing element can result in substitution, insertion and / or deletion of one or more nucleotides in an F8 gene.

[0109] As used herein, the term “integration efficiency of the editing element into the target locus” refers to the percentage of cells in a transduced population in which integration of the editing element into the target locus has occurred.

[0110] As used herein, the term “allelic frequency of integration of the editing element into the target locus” refers to the percentage of alleles in a population of transduced cells in which integration of the editing element into the target locus has occurred.II COMPOSITIONS

[0111] As used herein, “AAV” refers to adeno-associated virus. In certain embodiments, the AAV disclosed herein comprise: an AAV capsid comprising an AAV capsid protein; and a correction genome for editing a target locus in an F8 gene. The AAV capsid proteins that can be used in the AAV compositions disclosed herein include without limitation AAV capsid proteins and derivatives thereof.

[0112] As used herein, the term “AAVHSC” refers to adeno-associated virus transduced hematopoietic stem cells. Specifically, provided herein are AAV vectors that transduced primitive CD34+ hematopoietic stem cells. In embodiments, the genome editing methods referred to herein are AAVHSC mediated. In embodiments, tropism of AAVHSCs was not restricted to HSCs. In embodiments, intravenous injection of AAVHSC vectors demonstrate widespread systemic tropism. In embodiments, AAVHSCs are capable of crossing the bloodbrain barrier. In embodiments, AAVHSCs transduce neurons, astrocytes, oligodendrocytes, and satellite cells in the brain, spinal cord, dorsal root ganglia, as well as the peripheral nervous system.

[0113] As used herein, the term “1221 mutation” refers to the intron 22 inversion in the F8 gene. Generally, the intron 22 inversion refers to the intra-chromosomal homologous recombination that involves one of two ~10 kb segments of Xq28 chromosomal DNA. In embodiments, the recombination is at the distal position of these two segments.

[0114] As used herein, the term “capsid” refers to a protein shell of a virus comprising the genetic material of the virus.

[0115] Correction genomes useful in the AAV compositions disclosed herein generally comprise: (i) an editing element for editing a target locus in an F8 gene, (ii) a 5' homology arm nucleotide sequence 5' to the editing element having homology to a first genomic region 5' to the target locus, and (iii) a 3' homology arm nucleotide sequence 3' to the editing element having homology to a second genomic region 3' to the target locus, wherein the portion of the correction genome comprising the 5' homolog}' arm, editing element, and 3:homology arm can be in the sense or antisense orientation relative to the F8 gene locus.

[0116] As used herein, “editing elements” used in the correction genomes refer to insertion, deletion, or substitution of one or more nucleotides at the target locus. In certain embodiments, when correctly integrated by homologous recombination at the target locus, the editing element corrects a mutation in an F8 gene back to the wild-type F8 sequence or a functional equivalent thereof. In certain embodiments, the editing element comprises a wildtype or silently altered sequence of exons 1-13, 14, or 15-26 of an F8 gene. In certain embodiments, the editing element comprises at least a portion of an F8 coding sequence. In certain embodiments, the portion of the F8 coding sequence comprises the sequences of exons 1-13, 14, or 15-26 of an F8 gene.

[0117] In certain embodiments, the editing element comprises a portion of an F8 coding sequence (e.g., a portion of a wild-type F8 coding sequence, or a portion of a silently altered F8 coding sequence). Such editing elements can further comprise a splice acceptor site and / or an exogenous poly adenylation sequence. In certain embodiments, the editing element comprises 5' to 3': a splice acceptor site; a portion of an F8 coding sequence (e.g., a portion of a wild-type F8 coding sequence, or a portion of a silently altered F8 coding sequence); and an exogenous poly adenylation sequence. In certain embodiments, the portion of the F8 coding sequence comprises the sequences of exons 1-13, 14, or 15-26 of an F8 gene.

[0118] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 36. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 36. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity across the whole sequence of SEQ. ID NO: 36.

[0119] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 2. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 2. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 2.

[0120] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 37. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 37. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 37.

[0121] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 3. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 3. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 3.

[0122] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 38. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 38. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 38.

[0123] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 4. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 4. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 4.

[0124] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 39. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 39. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 39.

[0125] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 5. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 5. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 5.

[0126] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 40. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 40. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 40.

[0127] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 6. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 6. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 6.

[0128] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 41. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 41. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 41.

[0129] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 7. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 7. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 7.

[0130] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 42. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 42. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 42.

[0131] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 8. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 8. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 8.

[0132] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 43. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 43. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 43.

[0133] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 9. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 9. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 9.

[0134] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 44. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 44. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 44.

[0135] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 10. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 10. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 10.

[0136] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 45. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 45. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 45.

[0137] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 11. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 11. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 11.

[0138] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 46. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 46. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 46.

[0139] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 12. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 12. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 12.

[0140] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 47. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 47. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 47.

[0141] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 13. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 13. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 13.

[0142] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 48. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 48. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 48.

[0143] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 14. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 14. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 14.

[0144] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 49. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 49. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 49.

[0145] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 15. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 15. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 15.

[0146] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 50. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 50. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 50.

[0147] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 16. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 16. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 16.

[0148] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 51. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 51. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 51.

[0149] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 17. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 17. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 17.

[0150] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 52. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 52. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 52.

[0151] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 18. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 18. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 18.

[0152] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 53. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 53. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 53.

[0153] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 19. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 19. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 19.

[0154] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 54. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 54. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 54.

[0155] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 20. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 20. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 20.

[0156] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 55. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 55. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 55.

[0157] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 21. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 21. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 21.

[0158] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 56. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 56. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 56.

[0159] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 22. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 22. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 22.

[0160] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 57. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 57. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 57.

[0161] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 23. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 23. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 23.

[0162] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 58. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 58. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 58.

[0163] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 24. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 24. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 24.

[0164] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 59. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 59. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 59.

[0165] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 25. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 25. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 25.

[0166] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 60. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 60. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 60.

[0167] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 26. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 26. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 26.

[0168] In certain embodiments, the F8 coding sequence includes the nucleotide sequence of SEQ. ID NO: 61. In embodiments, the F8 coding sequence is the nucleotide sequence of SEQ. ID NO: 61. In embodiments, the F8 coding sequence is a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity' across the whole sequence of SEQ. ID NO: 61.

[0169] In certain embodiments, the F8 coding sequence includes the peptide sequence of SEQ. ID NO: 27. In embodiments, the F8 coding sequence is the peptide sequence of SEQ. ID NO: 27. In embodiments, the F8 coding sequence is a peptide sequence having at least 85% sequence identity across the whole sequence of SEQ. ID NO: 27. In embodiments, the F8 coding sequence is a peptide sequence having at least 86% sequence identity across the whole sequence of SEQ. ID NO: 27. In embodiments, the F8 coding sequence is a peptide sequence having at least 87% sequence identity across the whole sequence of SEQ. ID NO: 27. In embodiments, the F8 coding sequence is a peptide sequence having at least 88% sequence identity across the whole sequence of SEQ. ID NO: 27. In embodiments, the F8 coding sequence is a peptide sequence having at least 89% sequence identity across the whole sequence of SEQ. ID NO: 27. In embodiments, the FS coding sequence is a peptide sequence having at least 90% sequence identity across the whole sequence of SEQ. ID NO: 27. In embodiments, the F8 coding sequence is a peptide sequence having at least 91% sequence identity across the whole sequence of SEQ. ID NO: 27. In embodiments, the FS coding sequence is a peptide sequence having at least 92% sequence identity' across the whole sequence of SEQ. ID NO: 27. In embodiments, the FS coding sequence is a peptide sequence having at least 93% sequence identity across the whole sequence of SEQ. ID NO: 27. In embodiments, the F8 coding sequence is a peptide sequence having at least 94% sequence identity across the whole sequence of SEQ. ID NO: 27. In embodiments, the / N coding sequence is a peptide sequence having at least 95% sequence identity' across the whole sequence of SEQ. ID NO: 27. In embodiments, the F? coding sequence is a peptide sequence having at least 96% sequence identity across the whole sequence of SEQ. ID NO: 27. In embodiments, the F8 coding sequence is a peptide sequence having at least 97% sequenceidentity across the whole sequence of SEQ. ID NO: 27. In embodiments, the F8 coding sequence is a peptide sequence having at least 98% sequence identity across the whole sequence of SEQ. ID NO: 27. In embodiments, the FS coding sequence is a peptide sequence having at least 99% sequence identity across the whole sequence of SEQ. ID NO: 27. In embodiments, the F8 coding sequence is a peptide sequence has 100% sequence identity across the whole sequence of SEQ. ID NO: 27. In embodiments, the F8 coding sequence is a peptide sequence having 85-86%, 86-87%, 87-88%, 88-89%, 89-90%, 90-91%, 91-92%, 92- 93%, 93-94%, 94-95%, 95-96%, 96-97%, 97-98%, 98-99%, or 99-100% sequence identity across the whole sequence of SEQ. ID NO: 27. In embodiments, the F8 coding sequence is a peptide sequence having 86-87% sequence identity across the whole sequence of SEQ. ID NO: 27. In embodiments, the F8 coding sequence is a peptide sequence having 87-88% sequence identity across the whole sequence of SEQ. ID NO: 27. In embodiments, the F8 coding sequence is a peptide sequence having 88-89% sequence identity across the whole sequence of SEQ. ID NO: 27. In embodiments, the ? coding sequence is a peptide sequence having 89-90% sequence identity across the whole sequence of SEQ. ID NO: 27. In embodiments, the F8 coding sequence is a peptide sequence having 90-91% sequence identity across the whole sequence of SEQ. ID NO: 27. In embodiments, the / N coding sequence is a peptide sequence having 91-92% sequence identity across the whole sequence of SEQ. ID NO: 27. In embodiments, the F8 coding sequence is a peptide sequence having 92-93% sequence identity across the whole sequence of SEQ. ID NO: 27. In embodiments, the F8 coding sequence is a peptide sequence having 93-94% sequence identity across the whole sequence of SEQ. ID NO: 27. In embodiments, the F8 coding sequence is a peptide sequence having 94-95% sequence identity across the whole sequence of SEQ. ID NO: 27. In embodiments, the F8 coding sequence is a peptide sequence having 95-96% sequence identity across the whole sequence of SEQ. ID NO: 27. In embodiments, the / N coding sequence is a peptide sequence having 96-97% sequence identity across the whole sequence of SEQ. ID NO: 27. In embodiments, the F8 coding sequence is a peptide sequence having 97-98% sequence identity across the whole sequence of SEQ. ID NO: 27. In embodiments, the F8 coding sequence is a peptide sequence having 98-99% sequence identity across the whole sequence of SEQ. ID NO: 27. In embodiments, the F8 coding sequence is a peptide sequence having 99-100% sequence identity across the whole sequence of SEQ. ID NO: 27.

[0170] In certain embodiments, the F8 coding sequence includes the peptide sequence of SEQ. ID NO: 28. In embodiments, the F8 coding sequence is the peptide sequence of SEQ.ID NO: 28. In embodiments, the F8 coding sequence is a peptide sequence having at least 85% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the F8 coding sequence is a peptide sequence having at least 86% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the F8 coding sequence is a peptide sequence having at least 87% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the F8 coding sequence is a peptide sequence having at least 88% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the F8 coding sequence is a peptide sequence having at least 89% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the FS coding sequence is a peptide sequence having at least 90% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the F8 coding sequence is a peptide sequence having at least 91% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the / N coding sequence is a peptide sequence having at least 92% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, lhe NS' coding sequence is a peptide sequence having at least 93% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the F8 coding sequence is a peptide sequence having at least 94% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the FS coding sequence is a peptide sequence having at least 95% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the F? coding sequence is a peptide sequence having at least 96% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the F8 coding sequence is a peptide sequence having at least 97% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the NS’ coding sequence is a peptide sequence having at least 98% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the FS coding sequence is a peptide sequence having at least 99% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the F8 coding sequence is a peptide sequence has 100% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the F8 coding sequence is a peptide sequence having 85-86% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the F8 coding sequence is a peptide sequence having 86-87% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the F8 coding sequence is a peptide sequence having 87-88% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the FS coding sequence is a peptide sequence having 88-89% sequence identity across the whole sequence of SEQ. ID NO: 28. Inembodiments, the F8 coding sequence is a peptide sequence having 89-90% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the / N coding sequence is a peptide sequence having 90-91% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the F8 coding sequence is a peptide sequence having 91-92% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the F8 coding sequence is a peptide sequence having 92-93% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the F8 coding sequence is a peptide sequence having 93-94% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the F8 coding sequence is a peptide sequence having 94-95% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the S coding sequence is a peptide sequence having 95-96% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the F8 coding sequence is a peptide sequence having 96-97% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the F8 coding sequence is a peptide sequence having 97-98% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the F8 coding sequence is a peptide sequence having 98-99% sequence identity across the whole sequence of SEQ. ID NO: 28. In embodiments, the F8 coding sequence is a peptide sequence having 99-100% sequence identity across the whole sequence of SEQ. ID NO: 28.

[0171] In certain embodiments, the F8 coding sequence includes the peptide sequence of SEQ. ID NO: 29. In embodiments, the F8 coding sequence is the peptide sequence of SEQ. ID NO: 29. In embodiments, the F8 coding sequence is a peptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the F8 coding sequence is a peptide sequence having at least 86% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the F8 coding sequence is a peptide sequence having at least 87% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, theFS coding sequence is a peptide sequence having at least 88% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the F8 coding sequence is a peptide sequence having at least 89% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the FS coding sequence is a peptide sequence having at least 90% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the F8 coding sequence is a peptide sequence having at least 91% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the / N codingsequence is a peptide sequence having at least 92% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the / N coding sequence is a peptide sequence having at least 93% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the F8 coding sequence is a peptide sequence having at least 94% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the / N coding sequence is a peptide sequence having at least 95% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the F? coding sequence is a peptide sequence having at least 96% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the F8 coding sequence is a peptide sequence having at least 97% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the / N coding sequence is a peptide sequence having at least 98% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the FS coding sequence is a peptide sequence having at least 99% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the F8 coding sequence is a peptide sequence has 100% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the F8 coding sequence is a peptide sequence having 85-86% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the F8 coding sequence is a peptide sequence having 86-87% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the F8 coding sequence is a peptide sequence having 87-88% sequence identity across the whole sequence of SEQ. ID NO: 16. In embodiments, the FS coding sequence is a peptide sequence having 88-89% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the F8 coding sequence is a peptide sequence having 89-90% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the FS coding sequence is a peptide sequence having 90-91% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the F8 coding sequence is a peptide sequence having 91-92% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the F8 coding sequence is a peptide sequence having 92-93% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the F8 coding sequence is a peptide sequence having 93-94% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the F8 coding sequence is a peptide sequence having 94-95% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the / N coding sequence is a peptide sequence having 95-96% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the F8 coding sequence is a peptide sequence having96-97% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the F8 coding sequence is a peptide sequence having 97-98% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the F8 coding sequence is a peptide sequence having 98-99% sequence identity across the whole sequence of SEQ. ID NO: 29. In embodiments, the F8 coding sequence is a peptide sequence having 99-100% sequence identity across the whole sequence of SEQ. ID NO: 29.

[0172] The term “replication-defective recombinant adeno-associated virus” refers to packaging systems for recombinant preparation of a replication-defective AAV. Such packaging systems generally comprise: a Rep nucleotide sequence encoding one or more AAV Rep proteins; a Cap nucleotide sequence encoding one or more AAV Clade F capsid proteins as disclosed herein; and a correction genome for correction of the F8 gene as disclosed herein, wherein the packaging system is operative in a cell for enclosing the correction genome in the capsid to form the AAV.

[0173] In certain embodiments, the packaging system comprises a first vector comprising the Rep nucleotide sequence and the Cap nucleotide sequence, and a second vector comprising the correction genome. As used in the context of a packaging system as described herein, a “vector” refers to a nucleic acid molecule that is a vehicle for introducing nucleic acids into a cell (e g., a plasmid, a virus, a cosmid, an artificial chromosome, etc.) Any AAV Rep protein can be employed in the packaging systems disclosed herein. In embodiments of the packaging system, the first, second, and / or third vector are contained within one or more transfecting plasmids.

[0174] As used herein, the packing system may further comprise a third vector, e.g., a helper virus vector. The third vector may be an independent third vector, integral with the first vector, or integral with the second vector. In certain embodiments, the third vector comprises genes encoding helper virus proteins. The helper virus may be selected from, but not limited to, adenovirus, herpes virus (including herpes simplex virus (HSV)), poxvirus (such as vaccinia vims), cytomegalovirus (CMV), and baculovirus.Ill METHODS

[0175] In an aspect, provided herein is are methods for treating diseases associated with an F8 gene mutation.

[0176] In embodiments, the method comprises administering to the the subject an effective amount of a replication-defective recombinant adeno-associated virus (AAV) comprising: (a) an AAV capsid; and, (b) a correction genome comprising: (i) an editing element for editing a target locus in the F8 gene; (ii) a 5' homology arm nucleotide sequence 5' to the editing element having homology to a first genomic region 5' to the target locus; (iii) a 3' homology arm nucleotide sequence 3' to the editing element having homology to a second genomic region 3' to the target locus; and (IV) an F8 coding sequence; wherein: (A) the F8 coding sequence comprises at least two consecutive exons selected from the group consisting of SEQ. ID NOs: 2 to 13 and optionally SEQ. ID NO: 14 or a portion thereof; or (B) the F8 coding sequence comprises SEQ. ID NO: 14; or (C) the F8 coding sequence comprises at least two consecutive exons selected from the group consisting of SEQ. ID NOs: 15 to 26 and optionally SEQ. ID NO: 14 or portion thereof; and wherein an exogenous nuclease or a nucleotide sequence that encodes an exogenous nuclease is not co-administered to the subject.

[0177] In embodiments, the disease or disorder is associated with blood coagulation. In embodiments, the disease or disorder is hemophilia A. In embodiments, the mutation is selected from the group consisting of Table 1. In embodiments, the AAV capsid is an AAVHSC capsid.

[0178] In embodiments, the F8 coding sequence consists of the peptide sequences set forth in SEQ. ID NO: 27, SEQ. ID NO: 28, or SEQ. ID NO: 29. In embodiments, the / 'N coding sequence consists of the peptide sequences set forth in SEQ. ID NO: 27. In embodiments, the F8 coding sequence consists of the peptide sequences set forth in SEQ. ID NO: 28. In embodiments, the F8 coding sequence consists of the peptide sequences set forth in SEQ. ID NO: 29.

[0179] In embodiments, the method further comprises detecting a mutation in the F8 gene in a biological sample. In embodiments, the method further comprises detecting a mutation in the N-terminus F8 gene in a biological sample and then administering a correction genome comprising the peptide sequence set forth in SEQ. ID NO: 27 and optionally a portion of SEQ. ID NO: 28. In embodiments, the method further comprises detecting a mutation in the CEN portion of the F8 gene in a biological sample and then administering a correction genome comprising the peptide sequence set forth in SEQ. ID NO: 28. In embodiments, the method further comprises detecting a mutation in the C-terminus F8 gene in a biologicalsample and then administering a correction genome comprising the peptide sequence set forth in SEQ. ID NO: 29 and optionally a portion of SEQ. ID NO: 28.

[0180] The terms “treating”, or “treatment” refers to any indicia of success in the therapy or amelioration of an injury, disease, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; improving a patient’s phy sical or mental well-being.

[0181] “Treating” or “treatment” as used herein (and as well-understood in the art) also broadly includes any approach for obtaining beneficial or desired results in a subject’s condition, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of the extent of a disease, stabilizing (z.e., not worsening) the state of disease, prevention of a disease’s transmission or spread, delay or slowing of disease progression, amelioration or palliation of the disease state, diminishment of the reoccurrence of disease, and remission, whether partial or total and whether detectable or undetectable. In other words, “treatment” as used herein includes any cure, amelioration, or prevention of a disease. Treatment may prevent the disease from occurring; inhibit the disease’s spread; relieve the disease’s symptoms, fully or partially remove the disease’s underlying cause, shorten a disease’s duration, or do a combination of these things.

[0182] “Treating” and “treatment” as used herein include prophylactic treatment. Treatment methods include administering to a subject a therapeutically effective amount of an active agent. The administering step may consist of a single administration or may include a series of administrations. The length of the treatment period depends on a variety of factors, such as the severity of the condition, the age of the patient, the concentration of active agent, the activity of the compositions used in the treatment, or a combination thereof. It will also be appreciated that the effective dosage of an agent used for the treatment or prophylaxis may increase or decrease over the course of a particular treatment or prophy laxis regime. Changes in dosage may result and become apparent by standard diagnostic assays known in the art. In some instances, chronic administration may be required. For example, the compositions are administered to the subject in an amount and for a duration sufficient to treat the patient. In embodiments, the treating or treatment is no prophylactic treatment.

[0183] The term “prevent” refers to a decrease in the occurrence of disease symptoms in a patient. As indicated above, the prevention may be complete (no detectable symptoms) or partial, such that fewer symptoms are observed than would likely occur absent treatment.

[0184] “Patient” or “subject in need thereof’ refers to a living organism. Non-limiting examples include humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, and other non-mammahan animals. In aspects, a patient is human. In aspects, a patient is human that has cancer.

[0185] A “effective amount,” as used herein, is an amount sufficient for a compound to accomplish a stated purpose relative to the absence of the compound (e.g. achieve the effect for which it is administered, treat a disease, reduce a signaling pathway, or reduce one or more symptoms of a disease or condition). In these methods, the effective amount of the active agent (e.g., oncolytic virus, viral vector) described herein is an amount effective to accomplish the stated purpose of the method. An example of an “effective amount” is an amount sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms of a disease, which could also be referred to as a “therapeutically effective amount.” A “reduction” of a symptom or symptoms (and grammatical equivalents of this phrase) means decreasing of the severity or frequency of the symptom(s), or elimination of the symptom(s). The exact amounts will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins).

[0186] The term “therapeutically effective amount,” as used herein, refers to that amount of the therapeutic agent sufficient to ameliorate the disorder, as described above. For example, for the given parameter, a therapeutically effective amount will show an increase or decrease of at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100%. Therapeutic efficacy can also be expressed as “-fold” increase or decrease. For example, a therapeutically effective amount can have at least a 0.01-fold, 0.02-fold, 0.03- fold, 0.04-fold, 0.05-fold, 0.06-fold, 0.07-fold, 0.08-fold, 0.09-fold, 0.10-fold, 0.20-fold, 0.30-fold, 0.40-fold, 0.50-fold, 0.60-fold, 0.70-fold, 0.80-fold 0.90-fold, 1.0-fold, 1. 1-fold, 1.2-fold, 1.5-fold, 2-fold, 5-fold, or more effect over a control. For any compound describedherein, the therapeutically effective amount can be initially determined from cell culture assays. Target concentrations will be those concentrations of active compound(s) that are capable of achieving the methods described herein, as measured using the methods described herein or known in the art. As is in the art, therapeutically effective amounts for use in humans can also be determined from animal models. For example, a dose for humans can be formulated to achieve a concentration that has been found to be effective in animals.

[0187] Dosages may be varied depending upon the requirements of the patient and the compound being employed. The dose administered to a patient, in the context of the present disclosure, should be sufficient to effect a beneficial therapeutic response in the patient over time. The size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached. Dosage amounts and intervals can be adjusted individually to provide levels of the administered compound effective for the particular clinical indication being treated. This will provide a therapeutic regimen that is commensurate with the severity of the individual's disease state.

[0188] The term “administering” refers to intranasal administration, inhalation administration, oral administration, administration as a suppository, topical contact, intravenous, parenteral, intraperitoneal, intramuscular, intralesional, intrathecal, intranasal or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini- osmotic pump, to a subject. Administration is by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal). Parenteral administration includes, e.g., intravenous, intramuscular, intra- arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other modes of delivery include the use of lipid nanoparticles, aerosols, liposomal formulations, intravenous infusion, transdermal patches, and the like. In aspects, administering does not include administration of any active agent other than the oncolytic virus or viral vector. In aspects, administration is intranasal. In aspects, administration is intravenous.

[0189] “Co-administer” it is meant that a composition described herein is administered at the same time, just prior to, or just after the administration of one or more additional therapies. The compounds provided herein can be administered alone or can becoadministered to the patient. Coadministration is meant to include simultaneous or sequential administration of the compounds individually or in combination (more than one compound). Thus, the preparations can also be combined, when desired, with other active substances (e.g. to reduce metabolic degradation).EXAMPLES

[0190] The recombinant AAV vectors provided herein mediate highly efficient gene editing. Useful examples known in the art can also be found in International Application No. PCT / US2019 / 018502, herein incorporated by reference in its entirety.

[0191] Example 1

[0192] Hemophilia A is an X-linked, inherited, bleeding disorder caused by a deficiency of clotting Factor VIII. Despite progress in gene therapy for hemophilia A, concerns regarding the long-term durability of this treatment have emerged based on reports of significant decline in FVIII levels despite initially high expression. The present application provides a permanent, safe, and effective in vivo genome editing strategy for the correction of heterogeneous Factor 8 mutations associated with hemophilia A. To achieve durable correction of F8 mutations, 3 AAVHSC editing vectors were designed that were tiled across Exons 2-26 of the F8 gene to permanently correct 95% of the >3000 mutations scattered throughout the human Factor 8 gene.

[0193] The present application evaluates the utility of the AAVHSC editing platform to correct pathogenic mutations safely and permanently in the Factor 8 (F8) gene to cure hemophilia A. Advantageously, the design leverages the inherent ability of the stem cell derived AAVHSC to edit the genome using high fidelity homologous recombination as well as the in vivo tropism of AAVHSC for the liver. Three strategically designed AAVHSC genome editing vectors were tiled across Exons 2 to 26 of the F8 gene to correct -95% of heterogenous F8 mutations. These vectors were tiled consecutively along the length of the F8 gene with the exception of Exon 1. Coverage of Exon 1 was excluded since inclusion of this region would necessitate the use of homology arms (HAs) which extend into the promoter and 5’UTR. This in turn may lead to the formation of partial transcripts driven by the promoter, potentially resulting in dominant negative truncated FVIII.

[0194] N-terminal (N-Ter) Editing Vector

[0195] The N-terminal (N-Ter) editing vector was designed to correct mutations in Exons 2 to 13 of the F8 gene, representing 39% of heterogenous F8 mutations. A single editing vector for the correction of mutations in Exons 2-13 requires the replacement of 52 kb long genomic DNA sequence with a 2 kb codon-optimized (CO) cDNA. However editing this large genomic segment was successfully accomplished by using AAVHSC HR in primary human liver sinusoidal endothelial cells (LSEC), which are the primary producers of Factor VIII protein in vivo. Similar large genomic replacement has significant therapeutic implications for diseases beyond hemophilia.

[0196] The editing portion of the vector including left and right homology arms, codon optimized coding sequence of exon 2 to 13, linker, T2A, Venus reporter ORF and SV40 poly A signal were chemically synthesized. The insert was then released by Not I plus Sbf I restriction enzyme digestion and cloned into AAV vector that contained AAV2 5' and 3' ITRs resulting in packaging vector pSC435. Editing viral vector VSC425 was then generated with co-transfected capsid vectors and HSV helper virus.

[0197] Central (CEN) Exon 14 Editing Vector

[0198] The Central (CEN) Exon 14 editing vector was designed to correct mutations in Exon 14 representing 21% of / A mutations. The editing cassette encodes a CO 3.1 kb cDNA of Exon 14. Optimized HAs were designed to replace the entire Exon 14.

[0199] The editing portion of the vector including left and right homology arms, codon optimized coding sequence of exon 14 were chemically synthesized. The insert was then released by Not I plus Sbf I restriction enzyme digestion and cloned into AAV vector that contained AAV2 5' and 3' ITRs resulting in packaging vector pSC425. Editing viral vector VSC435 was then generated with co-transfected capsid vectors and HSV helper virus

[0200] C- terminal (C-Ter) Editing Vector

[0201] The C-terminal (C-Ter) editing vector was designed to correct mutations in Exons 15 to 26, representing 34% ofFS mutations. The editing cassette encodes a 1.8kb CO cDNA of Exons 15-26 with optimized HAs for the insertion of the CO cDNA at codon 1 of Exon 15 immediately after splice acceptor (SA) site at the end of Intron 14. The cDNA is followed by a polyadenylation (pA) and RNA termination signal.

[0202] The editing portion of the vector including left and right homology arms, codon optimized coding sequence of exon 15-26, linker, T2A, Venus reporter ORF and SV40 polyAsignal were chemically synthesized. The insert was then released by Not I plus Sbf I restriction enzyme digestion and cloned into AAV vector that contained AAV2 5' and 3' ITRs resulting in packaging vector pSC423. Editing viral vector VSC423 was then generated with co-transfected capsid vectors and HSV helper virus.

[0203] To facilitate identification of genome editing events, one set of corresponding editing vectors were designed to insert a promoterless Venus open reading frame (ORF) at the end of the correction cassette. The Venus ORF is preceded by a T2A self-cleaving peptide sequence and followed by a pA signal (Figure 2). The reporter gene Venus was expressed only after accurate in frame genomic insertion downstream from the chromosomal 1 '8 promoter. Quantification of Venus expression therefore served as a measure of editing efficiency. The therapeutic editing vectors are devoid of the of the Venus reporter (Figure 3). This allowed expression of the full length FVIII protein.

[0204] Transductions and Flow Analysis

[0205] The F8 editing vectors were designed to edit either the N-Ter (Exons 2-13), CEN (Exon 14) or C-Ter (Exons 15-16) regions of the F8 gene. The preclinical versions of the editing vectors also encode a promoterless Venus open reading frame (ORF) that were designed to be inserted following the last corrected exon upon successful editing. A T2A selfcleaving peptide precedes the Venus ORF to allow independent expression. Upon successful editing of the F8 gene, Venus is expressed from the chromosomal F8 promoter. Editing efficiency was measured by Venus expression in transduced cells.

[0206] Evaluation of Editing based on Venus Expression

[0207] Editing efficiency was evaluated in wild type primary human liver sinusoidal endothelial cells (LSECs) (Cell Systems, ACBRI566) or wild type primary human fibroblasts (AG21802). Cells were transduced with recombinant AAVHSC15 F8 editing vectors. Forty thousand cells of each type were transduced at multiplicity of infection (MOI) of 1.5X105, maintaining the volume of vector at less than 5% of the total culture volume. Cells were harvested after 48 hours and washed with PBS containing 2% fetal calf serum. Venus expression was measured in live cells using an Attune NxT flow cytometer (Invitrogen).Cells were gated on forward scatter and side scatter followed by DAPI exclusion. Data was analyzed using FlowJo software (FlowJo, LLC).

[0208] Venus in edited cells is shown in Figure 4. Means and standard deviations of GFP expression in edited cells are shown. Results represent 3 replicates for the N-Ter and C-Ter editing vectors in LSECs and 2 replicates for fibroblasts. Flow cytometric analysis showed that the AAVHSC N-Ter and C-Ter editing vectors were successfully edited F8 Exons 2-13 and Exons 15-26 respectively. Venus expression indicated correct editing of the targeted regions of the F8. The genome editing efficiencies ranged from 15% to 36% for LSECs ranged from and 18% to 23% for fibroblasts.Table 1. Mutations Associated with Hemophilia AINFORMAL SEQUENCE LISTINGTable 2. 3'-UTR SequenceTable 3. Codon Optimized Nucleotide SequencesTable 4. F8 codon optimized peptide sequencesTable 5. Editing Vector Seqeunces for Correction of MutationsTable 6. Wild-type Sequences of F8 GeneTable 7. Homology Arms for Editing Vectors

Claims

WHAT IS CLAIMED IS:

1. A method for correcting a mutation in an F8 gene in a cell, the method comprising transducing the cell with a replication-defective adeno-associated virus (AAV) comprising: a) an AAV capsid; and, b) an N-terminal (N-ter) correction genome comprising: (i) an editing element for editing a target locus in the F8 gene; (ii) a 5' homology arm nucleotide sequence 5' to the editing element having homology to a first genomic region 5' to the target locus; (iii) a 3' homology arm nucleotide sequence 3' to the editing element having homology to a second genomic region 3' to the target locus; and (iv) an F8 coding sequence; wherein the F8 coding sequence comprises at least two consecutive exons selected from the group consisting of exons 1 to 13 and exon 14; or a portion thereof of the F8 gene.

2. The method according to claim 1, wherein the F8 coding sequence comprises at least two consecutive exons selected from the group consisting of exons 2 to 13 as set forth in SEQ. ID NOs: 2 to 13 and exon 14 as set forth in SEQ. ID NO: 14 or a portion thereof.

3. The method according to claim 1, wherein the F8 coding sequence comprises at least two consecutive exons selected from the group consisting of exons 2 to 13 as set forth in SEQ. ID NOs: 2 to 13.

4. The method according to claim 1, wherein the F8 coding sequence comprises at least three consecutive exons selected from the group consisting of exons 2 to 13 as set forth in SEQ. ID NOs: 2 to 13.

5. The method according to claim 1, wherein the F8 coding sequence comprises at least four consecutive exons selected from the group consisting of exons 2 to 13 as set forth in SEQ. ID NOs: 2 to 13.

6. The method according to claim 1, wherein the F8 coding sequence comprises at least five consecutive exons selected from the group consisting of exons 2 to 13 as set forth in SEQ. ID NOs: 2 to 13.

7. The method according to claim 1, wherein the F8 coding sequence comprises at least six consecutive exons selected from the group consisting of exons 2 to 13 as set forth in SEQ. ID NOs: 2 to 13.

8. The method according to claim 1, wherein the F8 coding sequence comprises at least seven consecutive exons selected from the group consisting of exons 2 to 13 as set forth in SEQ. ID NOs: 2 to 13.

9. The method according to claim 1, wherein the F8 coding sequence comprises at least eight consecutive exons selected from the group consisting of exons 2 to 13 as set forth in SEQ. ID NOs: 2 to 13.

10. The method according to claim 1, wherein the F8 coding sequence comprises at least nine consecutive exons selected from the group consisting of exons 2 to 13 as set forth in SEQ. ID NOs: 2 to 13.

11. The method according to claim 1, wherein the F8 coding sequence comprises at least ten consecutive exons selected from the group consisting of exons 2 to 13 as set forth in SEQ. ID NOs: 2 to 13.

12. The method according to claim 1, wherein the F8 coding sequence comprises at least eleven c exons sequences selected from the group consisting of exons 2 to 13 as set forth in SEQ. ID NOs: 2 to 13.

13. The method according to claim 1, wherein the F8 coding sequence comprises twelve consecutive exons selected from the group consisting of exons 2 to 13 as set forth in SEQ. ID NOs: 2 to 13.

14. The method according to claim 1, wherein the F8 coding sequence comprises exons 2, 3, and 4.

15. The method according to claim 1, wherein the F8 coding sequence comprises exons 2, 3, and 4 as set forth in SEQ. ID NO: 2, SEQ. ID NO: 3, and SEQ. ID NO: 4.

16. The method according to claim 1, wherein the F8 coding sequence comprises exons 5 and 6.

17. The method according to claim 1, wherein the F8 coding sequence comprises exons 5 and 6 as set forth in SEQ. ID NO: 5 and SEQ. ID NO: 6.

18. The method according to claim 1, wherein the F8 coding sequence comprises exons 2 to 6.

19. The method according to claim 1, wherein the F8 coding sequence comprises exons 2 to 6 as set forth in SEQ. ID NO: 2 to SEQ. ID NO: 6.

20. The method according to claim 1, wherein the F8 coding sequence comprises exons 2 to 7.

21. The method according to claim 1, wherein the F8 coding sequence comprises exons 2 to 7 as set forth in SEQ. ID NO: 2 to SEQ. ID NO: 7.

22. The method according to claim 1, wherein the F8 coding sequence comprises exons 8 and 9.

23. The method according to claim 1 , wherein the F8 coding sequence comprises exons 8 and 9 as set forth in SEQ. ID NO: 8 and SEQ. ID NO: 9.

24. The method according to claim 1, wherein the F8 coding sequence comprises exons 10 and 11.

25. The method according to claim 1, wherein the F8 coding sequence comprises exons 10 and 11 as set forth in SEQ. ID NO: 10 and SEQ. ID NO: 11.

26. The method according to claim 1, wherein the F8 coding sequence comprises exons 8 to 11.

27. The method according to claim 1, wherein the F8 coding sequence comprises exons 8 to 11 as set forth in SEQ. ID NO: 8, SEQ. ID NO: 9, SEQ. ID NO: 10, and SEQ. ID NO: 11.

28. The method according to claim 1, wherein the F8 coding sequence comprises exons 8 to 12.

29. The method according to claim 1, wherein the F8 coding sequence comprises exons 8 to 12 as set forth in SEQ. ID NO: 8 to SEQ. ID NO: 12 of the F8 gene.

30. The method according to claim 1, wherein the F8 coding sequence comprises exons 8 to 13.

31. The method according to claim 1, wherein the F8 coding sequence comprises exons 8 to 13 as set forth in SEQ. ID NOs: 8 to 13 of the F8 gene.

32. The method according to claim 1, wherein the 5' homology arm consists of the nucleotide sequence set forth in SEQ. ID NO: 62 and the 3' homology arm consists of the nucleotide sequence set forth in SEQ. ID NO: 63.

33. The method according to claim 1, wherein the cell is transduced without co-transducing or co-administering an exogenous nuclease or a nucleotide sequence that encodes an exogenous nuclease.

34. A method for correcting a mutation in an F8 gene in a cell, the method comprising transducing the cell with a replication-defective adeno-associated virus (AAV) comprising: a) an AAV capsid; and, b) a central (CEN) correction genome comprising: (i) an editing element for editing a target locus in the F8 gene; (ii) a 5' homology arm nucleotide sequence 5' to the editing element having homology to a first genomic region 5' to the target locus; (iii) a 3' homology arm nucleotide sequence 3' to theediting element having homology to a second genomic region 3' to the target locus; and (iv) an F8 coding sequence; wherein the F8 coding sequence comprises exon 14 of the F8 gene.

35. The method of claim 34, wherein the F8 coding sequence comprises exon 14 as set forth in SEQ. ID NO: 14.

36. The method of claim 34, wherein the cell is transduced without cotransducing or co-administering an exogenous nuclease or a nucleotide sequence that encodes an exogenous nuclease.

37. The method according to claim 34, wherein the 5' homology arm consists of the nucleotide sequence set forth in SEQ. ID NO: 64 and the 3' homology arm consists of the nucleotide sequence set forth in SEQ. ID NO: 65.

38. A method for correcting a mutation in an F8 gene in a cell, the method comprising transducing the cell with a replication-defective adeno-associated virus (AAV) comprising: a) an AAV capsid; and, b) a C-terminal (C-ter) correction genome comprising: (i) an editing element for editing a target locus in the F8 gene; (ii) a 5' homology arm nucleotide sequence 5' to the editing element having homology to a first genomic region 5' to the target locus; (iii) a 3' homology arm nucleotide sequence 3' to the editing element having homology to a second genomic region 3' to the target locus; and (iv) an F8 coding sequence; wherein the F8 coding sequence comprises at least two consecutive exons selected from the group consisting of exons 15 to 26 and exon 14 or a portion thereof.

39. The method of claim 38, wherein the F8 coding sequence comprises at least two consecutive exons selected from the group consisting of exons 15 to 26 as set forth in SEQ. ID NOs: 15 to 26 and exon 14 or a portion thereof as set forth in SEQ. ID NO; 14.

40. The method of claim 38, wherein the F8 coding sequence comprises at least two consecutive exons selected from the group consisting of exons 15 to 26 as set forth in SEQ. ID NOs: 15 to 26.

41. The method of claim 38, wherein the F8 coding sequence comprises at least three consecutive exons selected from the group consisting of exons 15 to 26 as set forth in SEQ. ID NOs: 15 to 26.

42. The method of claim 38, wherein the F8 coding sequence comprises at least four consecutive exons selected from the group consisting of exons 15 to 26 as set forth in SEQ. ID NOs: 15 to 26.

43. The method of claim 38, wherein the F8 coding sequence comprises at least five consecutive exons selected from the group consisting of exons 15 to 26 as set forth in SEQ. ID NOs: 15 to 26.

44. The method of claim 38, wherein the F8 coding sequence comprises at least six consecutive exons selected from the group consisting of exons 15 to 26 as set forth in SEQ. ID NOs: 15 to 26.

45. The method of claim 38, wherein the F8 coding sequence comprises at least seven consecutive exons selected from the group consisting of exons 15 to 26 as set forth in SEQ. ID NOs: 15 to 26.

46. The method of claim 38, wherein the F8 coding sequence comprises at least eight consecutive exons selected from the group consisting of exons 15 to 26 as set forth in SEQ. ID NOs: 15 to 26.

47. The method of claim 38, wherein the F8 coding sequence comprises at least nine consecutive exons selected from the group consisting of exons 15 to 26 as set forth in SEQ. ID NOs: 15 to 26.

48. The method of claim 38, wherein the F8 coding sequence comprises at least ten consecutive exons selected from the group consisting of exons 15 to 26 as set forth in SEQ. ID NOs: 15 to 26.

49. The method of claim 38, wherein the F8 coding sequence comprises at least eleven consecutive exons selected from the group consisting of exons 15 to 26 as set forth in SEQ. ID NOs: 15 to 26.

50. The method of claim 38, wherein the F8 coding sequence comprises exons 16 to 19.

51. The method of claim 38, wherein the F8 coding sequence comprises exons 16 to 19 as set forth in SEQ. ID NOs: 16 to 19.

52. The method of claim 38, wherein the F8 coding sequence comprises exons 15 to 19.

53. The method of claim 38, wherein the F8 coding sequence comprises exons 15 to 19 as set forth in SEQ. ID NOs: 15 to 19.

54. The method of claim 38, wherein the F8 coding sequence comprises exons 20 to 22.

55. The method of claim 38, wherein the F8 coding sequence comprises SEQ. ID NOs: 20 to 22.

56. The method of claim 38, wherein the F8 coding sequence comprises exons 20 to 23.

57. The method of claim 38, wherein the F8 coding sequence comprises exons 20 to 23 as set forth in SEQ. ID NOs: 20 to 23.

58. The method of claim 38, wherein the F8 coding sequence comprises exons24 and 25.

59. The method of claim 38, wherein the F8 coding sequence comprises exons24 and 25 as set forth in SEQ. ID NOs: 24 and 25.

60. The method of claim 38, wherein the F8 coding sequence comprises exons 24 to 26.

61. The method of claim 38, wherein the F8 coding sequence comprises exons 24 to 26 as set forth in SEQ. ID NOs: 24 to 26.

62. The method of claim 38, wherein the cell is transduced without cotransducing or co-administering an exogenous nuclease or a nucleotide sequence that encodes an exogenous nuclease.

63. The method of claim 38, wherein the 5' homology arm consists of the nucleotide sequence set forth in SEQ. ID NO: 66 and the 3' homology arm consists of the nucleotide sequence set forth in SEQ. ID NO: 67.

64. The method of any one of the preceding claims, wherein the mutation is selected from the group consisting of Table 1.

65. The method of any one of the preceding claims, wherein the AAV capsid is an AAVHSC (adeno-associated virus and hematopoietic stem cell) capsid.

66. A method for treating a subject having a disease or disorder associated with a mutation in an F8 gene, the method comprising administering to the subject an effective amount of a replication-defective recombinant adeno-associated virus (AAV) comprising: a) an AAV capsid; and, b) a correction genome comprising: (i) an editing element for editing a target locus in the F8 gene; (ii) a 5' homology arm nucleotide sequence 5' to the editing element having homology to a first genomic region 5' to the target locus; (iii) a 3' homology arm nucleotide sequence 3' to the editing element having homology to a second genomic region 3' to the target locus; and (iv) an F8 coding sequence;I l l wherein:(A) the F8 coding sequence comprises at least two consecutive exons selected from the group consisting of exons 1 to 13 and exon 14 or a portion thereof; or(B) the F8 coding sequence comprises exon 14; or(C) the F8 coding sequence comprises at least two consecutive exons selected from the group consisting of exon 15 to 26 and exon 14 or a portion thereof; and, wherein an exogenous nuclease or a nucleotide sequence that encodes an exogenous nuclease is not co-administered to the subject.

67. The method of claim 61, wherein the F8 coding sequence comprises at least two consecutive exons selected from the group consisting of exons 2 to 13 as set forth in SEQ. ID NOs: 2 to 13 and exon 14 as set forth in SEQ. ID NO: 14 or a portion thereof.

68. The method of claim 61, wherein the F8 coding sequence comprises exon 14 as set forth in SEQ. ID NO: 14.

69. The method of claim 61, wherein the F8 coding sequence comprises at least two consecutive exons selected from the group consisting of exons 15 to 26 as set forth in SEQ. ID NOs: 15 to 26 and exon 14 as set forth in SEQ. ID NO: 14 or a portion thereof.

70. The method of claim 66, wherein the disease or disorder is associated with blood coagulation.71 . The method of claim 66, wherein the disease or disorder is hemophilia A.

72. The method of claim 66, wherein the mutation is selected from Table 1.

73. The method of claim 66, the AAV capsid is an AAVHSC capsid.

74. The method of claim 66, wherein the F8 coding sequence consists of the peptide sequences set forth in SEQ. ID NO: 27, SEQ. ID NO: 28, or SEQ. ID NO: 29.

75. A method for correcting a mutation in an F8 gene in a cell, the method comprising transducing the cell with a replication-defective adeno-associated virus (AAV) comprising: a) an AAV capsid; and b) a correction genome comprising: (i) an editing element for editing a target locus in the S gene; (ii) a 5' homology arm nucleotide sequence 5' to the editing element having homology to a first genomic region 5' to the target locus; (iii) a 3' homology arm nucleotide sequence 3' to the editing element having homology to a second genomic region 3' to the target locus; and (iv) anFS coding sequence; wherein the F8 coding sequence consists of the peptide sequences set forth in SEQ. ID NO: 27, SEQ. ID NO: 28, SEQ. ID NO: 29, or a portion thereof; and, wherein the cell is transduced without co-transducing or co-administering an exogenous nuclease or a nucleotide sequence that encodes an exogenous nuclease.

76. The method of claim 75, wherein the AAV capsid is an AAVHSC capsid.

77. The method of claim 75, wherein the F8 coding sequence consists of the peptide sequence set forth in SEQ. ID NO: 27 and optionally a portion of SEQ. ID NO: 28.

78. The method of claim 75, wherein the F8 coding sequence consists of the peptide sequence set forth in SEQ. ID NO: 28.

79. The method of claim 75, wherein the F8 coding sequence consists of the peptide sequence set forth in SEQ. ID NO: 29 and optionally a portion of SEQ. ID NO: 28.

80. A method for treating a subject having a disease or disorder associated with a mutation in an F8 gene, the method comprising administering to the subject an effective amount of a replication-defective recombinant adeno-associated virus (AAV) comprising: a) an AAV capsid; and b) a correction genome comprising: (i) an editing element for editing a target locus in the F8 gene; (ii) a 5' homology arm nucleotide sequence 5' to the editing element having homology to a first genomic region 5' to the targetlocus; (iii) a 3' homology arm nucleotide sequence 3' to the editing element having homology to a second genomic region 3' to the target locus, and (iv) an F8 coding sequence; wherein the F8 coding sequence consists of the peptide sequences set forth in SEQ. ID NO: 27, SEQ. ID NO: 28, SEQ. ID NO: 29, or portion thereof; and, wherein an exogenous nuclease or a nucleotide sequence that encodes an exogenous nuclease is not co-administered to the subject.

81. The method of claim 80, wherein the disease or disorder is associated with blood coagulation.

82. The method of claim 80, wherein the disease or disorder is hemophilia A.

83. The method of claim 80, wherein the AAV capsid is an AAVHSC capsid.

84. The method of claim 80, wherein the F8 coding sequence consists of the peptide sequence set forth in SEQ. ID NO: 27 and optionally a portion of SEQ. ID NO: 28.

85. The method of claim 80, wherein the F8 coding sequence consists of the peptide sequence set forth in SEQ. ID NO: 28.

86. The method of claim 80, wherein the F8 coding sequence consists of the peptide sequence set forth in SEQ. ID NO: 29 and optionally a portion of SEQ. ID NO: 28.

87. The method of claim 80 further comprising detecting a mutation in the F8 gene in a biological sample.

88. The method of claim 80 further comprising detecting a mutation in the N- terminus F8 gene in a biological sample and then administering a correction genome comprising the peptide sequence set forth in SEQ. ID NO: 27 and optionally a portion of SEQ. ID NO: 28.89 . The method of claim 80 further comprising detecting a mutation in the CEN portion of the F8 gene in a biological sample and then administering a correction genome comprising the peptide sequence set forth in SEQ. ID NO: 28.

90. The method of claim 80 further comprising detecting a mutation in the C- terminus F8 gene in a biological sample and then administering a correction genome comprising the peptide sequence set forth in SEQ. ID NO: 29 and optionally a portion of SEQ. ID NO: 28.

91. A replication-defective adeno-associated virus (AAV) comprising: a) an AAV capsid; and b) a correction genome comprising: (i) an editing element for editing a target locus in the AN gene; (ii) a 5' homology arm nucleotide sequence 5' to the editing element having homology to a first genomic region 5' to the target locus; (iii) a 3' homology arm nucleotide sequence 3' to the editing element having homology to a second genomic region 3' to the target locus; and (iv) an N coding sequence; wherein the F8 coding sequence consists of the peptide sequences set forth in SEQ. ID NO: 27, SEQ. ID NO: 28, SEQ. ID NO: 29, or a portion thereof.

92. The replication-defective AAV of claim 91, wherein the AAV capsid an AAVHSC capsid.

93. The replication-defective AAV of claim 91, wherein the F8 coding sequence consists of the peptide sequence set forth in SEQ. ID NO: 27 and optionally a portion of SEQ. ID NO: 28.

94. The replication-defective AAV of claim 91, wherein the F8 coding sequence consists of the peptide sequence set forth in SEQ. ID NO: 28.

95. The replication-defective AAV of claim 25, wherein the F8 coding sequence consists of the peptide sequence set forth in SEQ. ID NO: 29 and optionally a portion of SEQ. ID NO: 28.

96. A nucleic acid comprising:(i) an editing element for editing a target locus in an F8 gene;(ii) a 5' homology arm nucleotide sequence 5' to the editing element having homology to a first genomic region 5' to the target locus;(iii) a 3' homology arm nucleotide sequence 3' to the editing element having homology to a second genomic region 3' to the target locus; and,(iv) an F8 coding sequence; wherein the F8 coding sequence consists of the peptide sequences set forth in SEQ. ID NO: 27, SEQ. ID NO: 28, SEQ. ID NO: 29, or portion thereof.

97. The nucleic acid of claim 96, wherein the F8 coding sequence consists of the peptide sequence set forth in SEQ. ID NO: 27 and optionally a portion of SEQ. ID NO: 28.

98. The nucleic acid of claim 96, wherein the F8 coding sequence consists of the peptide sequence set forth in SEQ. ID NO: 28.

99. The nucleic acid of claim 96, wherein the F8 coding sequence consists of the peptide sequence set forth in SEQ. ID NO: 29 and optionally a portion of SEQ. ID NO: 28.

Citation Information

Patent Citations

  • Factor VIII mutation repair and tolerance induction

    US11083801B2

  • Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy

    US11286528B2

  • Delivery methods and compositions for nuclease-mediated genome engineering

    US20200102577A1

  • Genome-modified recombinant adeno-associated virus vectors

    US20210189428A1

  • Adeno-associated virus compositions for restoring f8 gene function and methods of use thereof

    US20220333138A1